

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Lipid management in Ischemic Stroke or Transient Ischemic Attack in China: Result from China National Stroke Registry III

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-069465
Article Type:	Original research
Date Submitted by the Author:	11-Nov-2022
Complete List of Authors:	Xu, Yuyuan; Beijing Tiantan Hospital, Chen, Weiqi; Beijing Tiantan Hospital Wang, Mengxing; Beijing Tiantan Hospital PAN, YUESONG; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases Li, Zixiao; Beijing Tiantan Hospital, Neurology Liu, Liping; Beijing Tiantan Hospital, Neurology; China National Clinical Research Center for Neurological Diseases, Zhao, Xingquan; Beijing Tiantan Hospital, Neurology Wang, Yilong; Beijing Tiantan Hospital, Department of Neurology Li, Hao; Beijing Tiantan Hospital Wang, Yongjun; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases Meng, Xia; Beijing Tiantan Hospital, Department of Neurology; Capital Medical University
Keywords:	Neurology < INTERNAL MEDICINE, Lipid disorders < DIABETES & ENDOCRINOLOGY, Stroke medicine < INTERNAL MEDICINE, Stroke < NEUROLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Lipid management in Ischemic Stroke or Transient Ischemic Attack in China:**
5
6 **Result from China National Stroke Registry III**
7
8
9

10
11 Yu-Yuan Xu, MD^{a, b}; Wei-Qi Chen, MD^{a, b}; Meng-Xing Wang, PhD^b; Yue-Song
12
13 Pan, PhD^b; Zi-Xiao Li, MD^{a, b}; Li-Ping Liu, MD^{a, b}; Xing-Quan Zhao, MD^{a, b}; Yi-
14
15 Long Wang, MD^{a, b}; Hao Li, PhD^b; Yong-Jun Wang, MD^{a, b, c, d}; Xia Meng, MD^{a, b};
16
17
18 on behalf of the CNSR-III Investigators
19
20
21

22
23
24
25 ^a Department of Neurology, Beijing Tiantan Hospital, Capital Medical University,
26
27 Beijing, China
28

29
30 ^b China National Clinical Research Center for Neurological Diseases, Beijing Tiantan
31
32 Hospital, Capital Medical University, Beijing, China
33

34
35 ^c Advanced Innovation Center for Human Brain Protection, Capital Medical
36
37 University, Beijing, China
38

39
40 ^d Research Unit of Artificial Intelligence in Cerebrovascular Disease, Chinese
41
42 Academy of Medical Sciences, 2019RU018
43
44
45

46
47
48 **Running title:** Lipid management in Ischemic Stroke or TIA
49

50
51 Correspondence to Dr. Xia Meng: No. 119 South 4th Ring West Road, Fengtai
52
53 District, Beijing 100070, China. Email: mengxia45@163.com. Phone: +86 10
54
55 59978245. Fax: +86 10 59973383.
56

57
58 Number of Tables: 7
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Number of Figures: 1

Word count: 3444

Keywords: low-density lipoprotein cholesterol, lipid-lowering treatment, ischemic stroke, second prevention

For peer review only

Abstract

Background and purpose: Dyslipidaemia is a significant risk factor for ischemic stroke and transient ischemic attack (TIA). This study aimed to assess the management of LDL-C and the goal achievement and to investigate the association between baseline low-density lipoprotein cholesterol (LDL-C) level, lipid-lowering treatment (LLT), and stroke recurrence in patients with ischemic stroke or TIA.

Methods: We derived data from the Third China National Stroke Registry (CNSR-III). The primary outcome was a new stroke, LDL-C goal (LDL-C<1.8mmol/L and LDL-C<1.4mmol/L, respectively) achievement rates, and LLT compliance within 3, 6, and 12 months. The association of baseline LDL-C level, LLT at discharge, and outcomes were assessed.

Results: Among the 15,166 patients, over 90% of patients received LLT during hospitalization and 2 weeks after discharge; the LLT compliance was 84.5% at 3 months, 75.6% at 6 months, and 64.8% at 12 months. LDL-C goal achievement for 1.8mmol/L and 1.4mmol/L was 35.4% and 17.6% at 12 months. LLT at discharge was associated with reduced risk of ischemic stroke recurrence (HR=0.687, 95% CI: 0.480-0.985, p=0.0411) at 3 months. The rate of LDL-C reduction from baseline to 3-month follow-up was not associated with a reduced risk of stroke recurrence, and major adverse cardiovascular events (MACE) at 12 months. Patients with baseline LDL-C \leq 1.4mmol/L had a numerically lower risk of stroke, ischemic stroke and MACE at both 3 months and 12 months.

1
2
3
4 **Conclusions:** The goal achievement of LDL-C has increased mildly in the stroke and
5
6 TIA population in mainland China. Lowered baseline LDL-C level was significantly
7
8 associated with a decreased short- and long-term risk of ischemic stroke among stroke
9
10 and TIA patients. LDL-C<1.4mmol/L might be a safe standard for this population.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Introduction

Low-density lipoprotein cholesterol (LDL-C) has been well established as an independent risk factor for ischemic stroke¹. Intensive lipid-lowering treatment (LLT) has been proven to reduce cardiovascular event recurrence in ischemic stroke/TIA patients. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study² showed that intensive atorvastatin treatment for five years reduced the risk of stroke recurrence up to 16% (HR 0.84, 95% CI 0.71-0.99; P<0.03) in ischemic stroke (IS) or transient ischemic attack (TIA). Recently, TST study³ also demonstrated that IS/TIA patients who had a target LDL-C level of less than 70 mg/dl (1.8mmol/L) had a lower risk of subsequent cardiovascular events than those who had a target range of 90 to 110 mg/dl (HR 0.78, 95% CI 0.61-0.98; P=0.04). Therefore, European Stroke Organisation (ESO) and American Stroke Association (ASA) both updated the IS/TIA second prevention guideline with a recommendation of LDL-C target goal to less than 70mg/dl (1.8mmol/L)^{4,5}.

However, there are still clinical questions not thoroughly investigated. Firstly, SPARCL and Treat Stroke to Target (TST) trials are randomized controlled trials conducted mainly in the Caucasian population^{2,6}, while studies focusing on the Asian population on lipid management in stroke patients are limited. Since there are more intracranial artery stenosis (ICAS)^{7,8} and cerebral small vessel disease (CSVD) patients in Asia^{9,10}, especially in east Asia, the conclusions of these two trials in Asia should be discreet. Secondly, there were inconsistencies and conflicts about whether the lower LDL-C level could increase the risk of intracranial hemorrhage (ICH),

1
2
3
4 especially during the acute or subacute phase. In the SPARCL study, subgroup
5
6 analysis indicated that atorvastatin treatment might increase the risk of ICH, which led
7
8 to a big concern for statin usage during the acute phase of IS/TIA ¹¹. In contrast, the
9
10 TST study showed that the incidence of ICH did not differ significantly between the
11
12 lower- and higher-target groups ³. Thirdly, with emerging evidence from non-statin
13
14 therapies such as IMPROVE-IT ¹², FOURIER ¹³, and ODYSSEY ¹⁴, a lower LDL-C
15
16 target of less than 1.4mmol/L or even 1.0mmol/L has been recommended by
17
18 international guidelines. However, the benefit of a lower LDL-C target other than
19
20 1.8mmol/L has not been investigated.

21
22 The Third China National Stroke Registry (CNSR-III) is one of the world's most
23
24 extensive IS/TIA cohort studies, which included comprehensive medical history,
25
26 centralized the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification
27
28 judication, and follow-up outcomes. We aim to collect data from CNSR-III to
29
30 investigate China's current lipid management situation and the association between
31
32 LDL-C level, LLT, and stroke recurrence in ischemic stroke or TIA patients.
33
34
35
36
37
38
39
40
41
42

43 **Methods**

44 **Patient and Public Involvement**

45
46 The development and organization of the study depended on stroke center
47
48 organizations and networks in China. Our co-investigators conducted a series of
49
50 meetings and discussions with national stroke patients. Patient education is always an
51
52 important work of the organization. We provided standard educational materials and a
53
54
55
56
57
58
59
60

1
2
3
4 research tutorial to each stroke center, to help to encourage familiarity with research
5
6 concepts and terminology. The discussion of study design and research method were
7
8 conveyed to the patients by co-investigators, using laypersons' language to facilitate
9
10 common understanding, and we solicited patients' feedback. We also conduct quality
11
12 control regularly to provide advice and service for patients. When results emerged, we
13
14 reviewed the results with patient co-investigators to obtain their perspectives and
15
16 feedback to ensure that we presented the findings in the most effective way beyond
17
18 the research community to general populations.
19
20
21
22
23
24
25

26 **Study design and participants**

27
28
29 We derived data from the CNSR-III database. The CNSR-III is a nationwide clinical
30
31 registry of ischemic stroke or transient ischemic attack (TIA) based on etiology,
32
33 imaging, and biological markers in China from August 2015 to March 2018 ¹⁵.
34
35 Consecutive patients were recruited consecutively if they were: (1) aged >18 years; (2)
36
37 patients with physician-diagnosed ischemic stroke or TIA; (3) within 7 days from the
38
39 onset of symptoms to enrolment; (4) patients who have provided consent to
40
41 participant in the study. Patients were excluded if they had silent cerebral infarction
42
43 with no symptoms or signs, or those who refused to participate in the registry. The
44
45 study protocol of the CNSR-III was approved by the ethics committee at Beijing
46
47 Tiantan Hospital (IRB approval number: KY2015-001-01) and all participating
48
49 centres. Every participant provided written informed consent before participation.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Among all the clinical centers included in CNSR-III, 169 centers voluntarily
5
6 participated in the prespecified blood biomarker substudy. All the patients at these
7
8 centers participated in this biomarker substudy. Patients participating in the biomarker
9
10 substudy provided a separate written informed consent form, including consent for
11
12 blood sample collection and further study of biomarkers.
13
14

15
16
17 A total of 15166 patients were eligible and had complete information at baseline.
18
19

20 **Data Collection and Management**

21
22
23 Patient information, including demographics, risk factors, comorbidities, medications,
24
25 selected laboratory tests, and hospital-level characteristics, were collected
26
27 systematically during hospitalization and at discharge by trained research coordinators
28
29 at each participating hospital. National Institutes of Health Stroke Scale (NIHSS)
30
31 score at admission, and ischemic stroke recurrence, composite vascular event, and
32
33 modified Rankin Scale (mRS) at 3 months and 1 year after stroke onset were also
34
35 collected.
36
37

38
39
40 Venous blood samples were collected from fasting patients within 24 hours from
41
42 admission. Serum specimens were extracted, aliquoted, and transported through the
43
44 cold chain to the central laboratory in Beijing Tiantan Hospital and stored at -80°C.
45
46

47
48
49 LDL-C measurements were centrally and blindly assayed by enzymatic method on the
50
51 Cobas 8000 analyzer c702 module (Roche Diagnostics, Mannheim, Germany).
52
53

54 **Follow-Up and Clinical Outcome Evaluations**

55
56
57
58
59
60

1
2
3
4 Patients were followed up by face-to-face interviews at 3 months and by telephone
5
6 interviews at 6 and 12 months by trained research coordinators based on a
7
8 standardized interview protocol. Information collected at each follow-up included
9
10 cardio-/cerebrovascular events, all causes of death, and medications use. Vascular
11
12 events were confirmed from the treating hospital, and death was either confirmed on a
13
14 death certificate from the attending hospital or the local civil registry.
15
16
17

18
19 The primary outcome was a new stroke (defined as a new neurological deficit lasting
20
21 more than 24 hours or re-hospitalization with a diagnosis of ischemic stroke,
22
23 intracerebral hemorrhage, and subarachnoid hemorrhage), LDL-C goal (LDL-
24
25 C<1.4mmol/L, and LDL-C<1.8mmol/L, respectively) achievement rates and LLT
26
27 compliance in China within 3, 6, and 12 months. The secondary outcomes included
28
29 major adverse cardiovascular events (including stroke, myocardial infarction, or
30
31 vascular death) and all caused death at 3 months and 12 months.
32
33
34
35
36

37 All reported efficacy and safety outcomes were verified by a central independent
38
39 adjudication committee blinded to study treatment assignments and baseline LDL-C
40
41 level.
42
43
44

45 Patients were categorized into four groups according to baseline LDL-C levels and
46
47 lipid-lowering treatment during hospitalization and after discharge: LDL-
48
49 C≤1.4mmol/L, 1.4mmol/L<LDL-C ≤1.8mmol/L, 1.8 mmol/L<LDL≤2.6mmol/L,
50
51 LDL>2.6mmol/L.
52
53
54

55 LLT compliance was defined as the continuation of LLT medication from discharge
56
57 to 3, 6, or 12 months after the onset of symptoms. Patients assigned to LLT at
58
59
60

1
2
3
4 discharge but later discontinuing LLT at any follow-up point within 3, 6, or 12
5
6 months were considered “non-persistent”. Patients were considered persistent if they
7
8 discontinued one medication but took another statin medication within 3, 6, or 12
9
10 months.
11
12
13
14

15 **Statistical analysis**

16
17
18
19 Baseline variables were presented as median with interquartile range (IQR) for
20
21 continuous variables and percentages for categorical variables.
22
23

24 To analyze the association of baseline LDL-C levels and outcomes, we only included
25
26 those subjects who provided 3-month or 12-month bio-sample. Univariate and
27
28 multivariate Cox proportional hazard regression models were used. The model
29
30 included the following covariates: age, sex, education, current smoking, heavy
31
32 drinking, medical history, stroke severity on the NIHSS, history of stroke, history of
33
34 diabetes, and history of hypertension. Adjusted hazard ratios (HRs) with 95%
35
36 confidence intervals (CIs) were calculated. The dose-response-relationship curves
37
38 were also presented.
39
40
41
42
43
44

45 To analyze the effect of discharge LLT on outcomes, we excluded subjects who
46
47 reached the end point (stroke recurrence or MACE, death, and loss to follow-up)
48
49 during hospitalization. We performed a univariate model and multivariable analysis
50
51 by adjusting for age, sex, education, current smoking, heavy drinking, medical
52
53 history, stroke severity on the NIHSS, history of stroke, history of diabetes, and
54
55 history of hypertension.
56
57
58
59
60

In addition, to analyze the association of 3-month LDL-C change with stroke recurrence and MACE in 12 months, we excluded subjects who reached the end point (stroke recurrence or MACE, death, and loss to follow-up) within 3 months.

Related statistical analyses in the study was performed by SAS 9.4 software. All statistical analysis adopted a two-sided test which will be performed at a 5% significance level.

Results

Characteristics of study participants

From August 2015 to March 2018, a total of 15166 patients with acute stroke and TIA were recruited to the CNSR-III trial and entered our final analysis. The average age of 62.2±11.3 years, 31.7% of patients were women, 14146 (93.3%) had an index event of stroke, and 1020 (6.7%) had a TIA ¹⁵.

Baseline LDL-C levels

There were 10,738 patients in LDL-C analysis set: 1407 (13.1%), 1636 (15.2%), 3655 (34.0%), and 4040 (37.6%) patients with an LDL-C ≤1.4mmol/L, LDL-C 1.4–1.8mmol/L, LDL-C 1.8–2.6mmol/L, LDL-C ≥ 2.6mmol/L, respectively (**Table 1**).

Table 1. Baseline Characteristics for the LDL-C analysis set

Variables	LDL≤1.4mmol/L N=1407	1.4 < LDL≤1.8mmol/L N=1636	1.8 < LDL≤2.6mmol/L N=3655	LDL>2.6mmol/L N=4040	P Value*
Women, n (%)	378 (26.9)	439 (26.8)	1057 (28.9)	1517 (37.6)	<0.001
Mean age, years (SD)	60.8±11.9	62.4±11.3	62.2±11.3	62.8±11.1	<0.001
Ethnicity (non-Han), n (%)	30 (2.1)	49 (3.0)	122 (3.3)	104 (2.6)	0.07
Current smoker, n (%)	435 (30.9)	525 (32.1)	1239 (33.9)	1198 (29.7)	<0.001
Heavy drinker, n (%)*	185 (13.2)	210 (12.8)	545 (14.9)	589 (14.6)	0.12

1						
2						
3	Triglycerides (IQR)	1.3 (0.9-1.9)	1.3 (1.0-1.8)	1.3 (1.0-1.8)	1.5 (1.1-2.0)	<0.001
4	TC, mmol/L	2.7 (2.4-3.1)	3.2 (3.0-3.5)	3.8 (3.5-4.1)	4.9 (4.5-5.5)	<0.001
5	HDL-C, mmol/L	0.8 (0.7-1.0)	0.9 (0.8-1.1)	0.9 (0.8-1.1)	1.0 (0.8-1.2)	<0.001
6	LDL-C, mmol/L	1.2 (1.0-1.3)	1.6 (1.5-1.7)	2.2 (2.0-2.4)	3.2 (2.9-3.8)	<0.001
7	BMI	24.4 (22.5-26.4)	24.5 (22.7-26.6)	24.4 (22.5-26.4)	24.5 (22.7-26.7)	0.06
8	Systolic pressure, mmHg	145.0 (132.5-160.0)	146.5 (133.0-161.0)	148.5 (135.0-163.5)	150.0 (136.0-166.5)	<0.001
9	Medical history, n (%)					
10	Ischemic stroke	369 (26.2)	429 (26.2)	715 (19.6)	748 (18.5)	<0.001
11	TIA	44 (3.1)	46 (2.8)	115 (3.6)	102 (2.5)	0.38
12	Coronary heart diseases	147 (10.5)	193 (11.8)	366 (10.0)	449 (11.1)	0.20
13	Atrial fibrillation	93 (6.6)	124 (7.6)	272 (7.4)	257 (6.4)	0.19
14	Hypertension	897 (63.8)	1045 (63.9)	2295 (62.8)	2516 (62.3)	0.62
15	Diabetes mellitus	386 (27.4)	394 (24.1)	824 (22.5)	960 (23.8)	0.004
16	Hypercholesterolemia	119 (8.5)	120 (7.3)	302 (8.3)	341 (8.4)	0.56
17	NIHSS at admission, median (IQR)	3.0 (1.0-6.0)	3.0 (1.0-6.0)	3.0 (1.0-6.0)	3.0 (1.0-6.0)	<0.001
18	NIHSS 0-3	743 (52.8)	914 (55.9)	1974 (54.0)	2073 (51.3)	0.009
19	NIHSS ≥4	664 (47.2)	722 (44.1)	1681 (46.0)	1967 (48.7)	
20	mRS (IQR)	0 (0-1.0)	0 (0-1.0)	0 (0-1.0)	0 (0-0)	<0.001
21	Stroke subtype, n (%)					
22	LAA	303 (21.5)	390 (23.8)	933 (25.5)	1092 (27.0)	0.0095
23	CE	81 (5.8)	96 (5.9)	251 (6.9)	256 (6.3)	
24	SAO	312 (22.2)	359 (21.9)	740 (20.3)	819 (20.3)	
25	Other	21 (1.5)	16 (1.0)	38 (1.0)	47 (1.2)	
26	Unknown	690 (49.0)	775 (47.4)	1693 (46.3)	1826 (45.2)	
27	Antiplatelet therapy, n (%)	1357 (97.4)	1569 (97.1)	3504 (96.7)	3894 (97.0)	0.57
28	LLT, n (%)	1359 (97.6)	1558 (96.4)	3498 (96.5)	3897 (97.1)	0.15
29	Statin, n (%)	1355 (97.3)	1556 (96.3)	3491 (96.3)	3887 (96.9)	0.27

TC: total cholesterol. HDL-C: high-density lipoprotein cholesterol. LDL-C: low-density lipoprotein cholesterol. BMI: body mass index. TIA: transient ischemic attack. NIHSS: National Institutes of Health Stroke Scale. mRS: modified Rankin Scale. LAA: large artery atherosclerosis. CE: cardiogenic embolism. SAO: small artery occlusion. LLT: lipid-lowering therapy.

Patients in the lower baseline LDL-C level group (≤ 1.4 mmol/L) were more likely to be younger ($p < 0.0001$) and had a greater prevalence of cardiovascular risk factors (previous stroke, hypertension, hypercholesterolemia, diabetes mellitus, and history of stroke) ($p < 0.0001$) and a lower level of triglycerides, total cholesterol and high-density lipoprotein (HDL) ($p < 0.0001$). About 97% of included patients had medication history of antiplatelet and lipid-lowering therapy, and the rates showed no difference among the four groups.

Association between baseline LDL-C levels and outcomes at 3 months and 12 months

There were 656 (6.11%) new stroke occurrences at 3 months and 1037 (9.66%) at 12 months (Table 2).

Table 2. Association between baseline LDL-C levels and outcomes at 3 months and 12 months

	Total	Events (n%)	HR (95% CI) Unadjusted	P value	HR (95% CI) Adjusted	P value
3 months						
Stroke recurrence						
LDL≤1.4mmol/L	1407	69 (4.9)	0.72 (0.55-0.94)	0.01	0.74 (0.57-0.97)	0.03
1.4<LDL≤1.8mmol/L	1636	95 (5.8)	0.85 (0.68-1.08)	0.18	0.89 (0.70-1.12)	0.32
1.8<LDL≤2.6mmol/L	3655	219 (6.0)	0.88 (0.74-1.05)	0.17	0.91 (0.76-1.08)	0.28
LDL>2.6mmol/L	4040	273 (6.8)	Reference	-	Reference	-
Ischemic stroke						
LDL≤1.4mmol/L	1407	65 (4.6)	0.72 (0.55-0.95)	0.02	0.74 (0.56-0.98)	0.03
1.4<LDL≤1.8mmol/L	1636	88 (5.4)	0.84 (0.66-1.07)	0.16	0.87 (0.68-1.11)	0.27
1.8<LDL≤2.6mmol/L	3655	201 (5.5)	0.86 (0.72-1.04)	0.11	0.89 (0.74-1.07)	0.22
LDL>2.6mmol/L	4040	257 (6.4)	Reference	-	Reference	-
Hemorrhagic stroke						
LDL≤1.4mmol/L	1407	4 (0.3)	0.52 (0.18-1.51)	0.23	0.55 (0.19-1.61)	0.28
1.4<LDL≤1.8mmol/L	1636	9 (0.6)	1.01 (0.46-2.19)	0.98	1.03 (0.47-2.26)	0.93
1.8<LDL≤2.6mmol/L	3655	20 (0.6)	1.00 (0.55-1.84)	0.99	0.93 (0.50-1.73)	0.82
LDL>2.6mmol/L	4040	22 (0.5)	Reference	-	Reference	-
MACE						
LDL≤1.4mmol/L	1407	71 (5.1)	0.72 (0.56-0.94)	0.01	0.75 (0.57-0.97)	0.03
1.4<LDL≤1.8mmol/L	1636	100 (6.1)	0.88 (0.70-1.10)	0.27	0.91 (0.72-1.15)	0.42
1.8<LDL≤2.6mmol/L	3655	231 (6.3)	0.91 (0.77-1.08)	0.29	0.93 (0.78-1.11)	0.43
LDL>2.6mmol/L	4040	279 (6.9)	Reference	-	Reference	-
12 months						
Stroke recurrence						
LDL≤1.4mmol/L	1407	114 (8.1)	0.76 (0.62-0.93)	0.009	0.77 (0.62-0.95)	0.01
1.4<LDL≤1.8mmol/L	1636	158 (9.7)	0.91 (0.76-1.08)	0.30	0.92 (0.76-1.10)	0.36
1.8<LDL≤2.6mmol/L	3655	339 (9.7)	0.87 (0.76-1.01)	0.06	0.89 (0.77-1.03)	0.12
LDL>2.6mmol/L	4040	426 (10.5)	Reference	-	Reference	-
Ischemic stroke						
LDL≤1.4mmol/L	1407	102 (7.6)	0.72 (0.58-0.90)	0.004	0.73 (0.59-0.91)	0.005
1.4<LDL≤1.8mmol/L	1636	145 (8.9)	0.89 (0.73-1.07)	0.22	0.90 (0.74-1.09)	0.27
1.8<LDL≤2.6mmol/L	3655	304 (8.3)	0.83 (0.72-0.97)	0.02	0.86 (0.74-1.00)	0.04
LDL>2.6mmol/L	4040	400 (9.9)	Reference	-	Reference	-
Hemorrhagic stroke						
LDL≤1.4mmol/L	1407	12 (0.9)	0.96 (0.50-1.84)	0.89	0.97 (0.50-1.88)	0.93
1.4<LDL≤1.8mmol/L	1636	15 (0.9)	1.03 (0.56-1.87)	0.94	1.02 (0.56-1.88)	0.95
1.8<LDL≤2.6mmol/L	3655	37 (1.0)	1.13 (0.72-1.80)	0.59	1.10 (0.69-1.75)	0.69
LDL>2.6mmol/L	4040	36 (0.9)	Reference	-	Reference	-

MACE

LDL≤1.4mmol/L	1407	119 (8.5)	0.76 (0.62-0.93)	0.008	0.77 (0.62-0.94)	0.01
1.4<LDL≤1.8mmol/L	1636	170 (10.4)	0.94 (0.79-1.12)	0.47	0.94 (0.79-1.13)	0.50
1.8<LDL≤2.6mmol/L	3655	363 (9.9)	0.90 (0.78-1.03)	0.13	0.91 (0.79-1.05)	0.20
LDL>2.6mmol/L	4040	444 (11.0)	Reference	-	Reference	-

LDL-C: low-density lipoprotein cholesterol. MACE: major adverse cardiovascular events.

Compared with patients with other LDL-C level subgroups, patients with LDL-C ≤1.4mmol/L had a numerically lower risk of stroke (HR=0.742, 95% CI: 0.568-0.970, p=0.0291), ischaemic stroke (HR=0.741, 95% CI: 0.562-0.976, p=0.0329) and MACE (HR=0.746, 95% CI: 0.573-0.972, p=0.0297) at 3 months. Similar results were found for the outcome of stroke (HR=0.767, 95% CI: 0.622-0.946, p=0.0131), ischaemic stroke (HR=0.731, 95% CI: 0.587-0.911, p=0.0052) and MACE (HR=0.766, 95% CI: 0.624-0.940, p=0.0106) in 12 months. Lower baseline LDL-C level was not associated with an increased risk of hemorrhagic stroke at both 3 months and 12 months (**Table 2**). Using a Cox regression model with restricted cubic splines, a larger magnitude of associations was also found between baseline LDL-C level and risk of stroke, ischemic stroke, hemorrhagic stroke, and MACE (**Figure 1**).

Lipid-lowering management, LLT compliance, and association of discharge LLT and outcomes

LLT management and compliance of the included patients during hospitalization, at discharge, 3 months, 6 months, and 12 months were shown in **Table 3**.

Table 3. Lipid-lowering Treatment (LLT) and the compliance of patients in

CNSR-III

	Hospitalization	Discharge	3 months	6 months	12 months
Non LLT	547 (3.6)	1300 (8.6)	2590 (17.4)	3007 (22.4)	3754 (26.0)
LLT	14506 (96.4)	13831 (91.4)	12271 (82.6)	11726 (77.6)	10682 (74.0)

Compliance

Non-Persistent	/	/	2147 (15.5)	3382 (24.5)	4863 (35.2)
Persistent	/	/	11684 (84.5)	10449 (75.6)	8968 (64.8)

Over 90% of patients received LLT during hospitalization and 2 weeks after

discharge. The LLT compliance was 84.5% at 3 months, 75.6% at 6 months, and

64.8% at 12 months. The drug regimens of lipid-lowering treatment of the patients in

CNSR-III in 3 months, 6 months, and 12 months were shown in **Table 4**.

Table 4. Lipid-lowering Treatment of the included patients in CNSR-III at 3-month, 6-month, 12-month follow-up (n=15166)

Treatment	Patients with statins, N (%)				
	Hospitalization	Discharge	3 months	6 months	12 months
Atorvastatin	10527 (69.41)	9851 (64.95)	8656 (57.08)	8228 (54.25)	7470 (49.25)
<40mg	7442 (70.71)	8770 (89.03)	8284 (95.7)	7963 (96.78)	7269 (97.35)
≥40mg	3083 (29.29)	1081 (10.97)	372 (4.3)	265 (3.22)	198 (2.65)
Rosuvastatin	3546 (23.38)	3395 (22.39)	2903 (19.14)	2779 (18.32)	2489 (16.41)
<20mg	2876 (81.15)	2983 (87.86)	2650 (91.38)	2536 (91.29)	2313 (92.93)
≥20mg	668 (18.85)	412 (12.14)	250 (8.62)	242 (8.71)	176 (7.07)
Simvastatin	272 (1.79)	239 (1.58)	390 (2.57)	411 (2.71)	444 (2.93)
Pravastatin	166 (1.09)	165 (1.09)	137 (0.9)	128 (0.84)	100 (0.66)
lovastatin	25 (0.16)	24 (0.16)	33 (0.22)	33 (0.22)	30 (0.2)
Fluvastatin	54 (0.36)	53 (0.35)	52 (0.34)	43 (0.28)	47 (0.31)
Pravastatin	61 (0.40)	78 (0.51)	70 (0.46)	64 (0.42)	61 (0.4)

Compared with the non-discharge LLT group, LLT at discharge was associated with

reduced risk of ischemic stroke (HR=0.65, 95% CI: 0.45-0.94, p=0.02) and stroke

recurrence (HR=0.69, 95% CI: 0.48-0.99, p=0.04) at 3 months (**Table 5**).

Table 5. The association of Discharge Lipid Lowering Therapy (LLT) and outcomes

	Total	Events, (n%)	HR (95% CI) Unadjusted	P value	HR (95% CI) Adjusted	P value
3 months						
Stroke recurrence						
Discharge LLT	13248	269 (2.0%)	0.68(0.48-0.96)	0.03	0.69(0.48-0.99)	0.04
Non discharge LLT	1181	35 (3.0%)	Reference		Reference	
Ischemic stroke						
Discharge LLT	13263	245 (1.9%)	0.68(0.47-0.98)	0.04	0.65(0.45-0.94)	0.02
Non discharge LLT	1188	32 (2.7%)	Reference		Reference	
Hemorrhagic stroke						

Discharge LLT	13740	31 (0.2%)	0.71(0.25-2.01)	0.52	1.19(0.36-3.98)	0.78
Non discharge LLT	1266	4 (0.3%)	Reference		Reference	
MACE						
Discharge LLT	13248	299 (2.3%)	0.71(0.51-1.003)	0.052	0.74(0.52-1.04)	0.08
Non discharge LLT	1181	37 (3.1%)	Reference		Reference	
12 months						
Stroke recurrence						
Discharge LLT	13248	758 (5.7%)	0.88(0.7-1.12)	0.30	0.89(0.7-1.14)	0.36
Non discharge LLT	1181	75 (6.4%)	Reference		Reference	
Ischemic stroke						
Discharge LLT	13263	683 (5.2%)	0.87(0.68-1.11)	0.26	0.86(0.67-1.10)	0.23
Non discharge LLT	1188	69 (5.8%)	Reference		Reference	
Hemorrhagic stroke						
Discharge LLT	13740	86 (0.6%)	0.97(0.47-2.00)	0.94	1.23(0.56-2.69)	0.60
Non discharge LLT	1266	8 (0.6%)	Reference		Reference	
MACE						
Discharge LLT	13248	838 (6.3%)	0.94(0.75-1.19)	0.60	0.96(0.76-1.21)	0.72
Non discharge LLT	1181	78(6.6%)	Reference		Reference	

Patients who reached the end point (stroke recurrence or MACE, death, and loss to follow-up) during hospitalization were excluded.

LDL-C goal achievement and change of LDL-C from baseline to 3 months with outcomes at 12 months

The overall blood lipid level at baseline, 3-month, and 12-month follow-up were shown in **Table 6**. LDL-C goal achievement for 1.8mmol/L were 28.3% at baseline, 46.7% at 3 months, and 35.4% at 12 months, respectively; while LDL-C goal achievement for 1.4mmol/L were 13.1% at baseline, 25.6% at 3 months, and 17.6% at 12 months, respectively.

Table 6. Blood Lipid Level of the included patients at baseline, 3 months and 1 year in CNSR-III

Lipids, mmol/L	Baseline N=10738	3M N=6034	12M N=4899
Median triglycerides (IQR), mmol/L	1.37(1.03-1.87)	1.32(0.98-1.81)	1.46(1.04-2.16)
Total cholesterol, mmol/L	3.97(3.31-4.72)	3.74(3.13-4.54)	3.92(3.25-4.76)
HDL-C, mmol/L	0.93(0.78-1.12)	1.02(0.86-1.21)	0.99(0.79-1.2)
LDL-C, mmol/L	2.31(1.73-2.97)	1.87(1.39-2.55)	2.14(1.57-2.87)
LDL <1.4mmol/L, n (%)	1407 (13.1)	1547 (25.6)	862 (17.6)
1.4 < LDL ≤1.8mmol/L, n (%)	1636 (15.2)	1272 (21.1)	872 (17.8)

1.8 < LDL ≤ 2.6 mmol/L, n (%)	3655 (34.0)	1785 (29.6)	1533 (31.3)
LDL > 2.6 mmol/L, n (%)	4040 (37.6)	1430 (23.7)	1632 (33.3)

HDL-C: high-density lipoprotein cholesterol. LDL-C: low-density lipoprotein cholesterol.

We did not find that the LDL-C reduction rate from baseline to 3-month follow-up was associated with reduced risk of stroke and MACE at 12 months (Table 7).

Table 7. Association of change of LDL-C from baseline to 3 months with outcomes at 12 months

Percentage of LDL level decrease (compared to baseline)	Total	Events, (n%)	HR (95% CI) unadjusted	P value	HR (95% CI) adjusted	P value
12 months						
Stroke recurrence*						
<30%, n (%)	3526	137 (3.9)	1.48 (0.92-2.39)	0.11	1.42 (0.87-2.30)	0.16
30-50%, n (%)	1146	45 (3.9)	1.50 (0.88-2.56)	0.14	1.44 (0.84-2.47)	0.19
>50%, n (%)	718	19 (2.7)	Reference		Reference	
MACE‡						
<30%, n (%)	3526	149 (4.2)	1.46 (0.92-2.20)	0.11	1.39 (0.88-2.21)	0.16
30-50%, n (%)	1146	47 (4.1)	1.41 (0.84-2.36)	0.19	1.36 (0.81-2.28)	0.24
>50%, n (%)	718	21 (2.9)	Reference		Reference	

* Patients with stroke recurrence, death, and loss to follow-up within 3 months were excluded.

‡ Patients with MACE, death, and loss to follow-up within 3 months were excluded.

Discussion

This national hospital-based study described the current LDL level and LLT of stroke patients in the real world. We described the LLT management and LDL-C goal achievement and found that lowered baseline LDL-C level was associated with a decreased risk of new ischaemic stroke and MACE at both 3 months and 12 months, without increasing risk of intracranial hemorrhage. In addition, LLT at discharge was associated with a reduced risk of CV events at 3 and 12 months. Our study may have important clinical implications with the large sample size of LDL-C levels of stroke patients and comprehensive prognostic characteristics recorded.

1
2
3
4 Firstly, LDL-C of 1.4 mmol/l might be a reasonable target for the high-risk
5
6 population. Our study indicated that the LDL \leq 1.4 mmol/L group, with the highest risk
7
8 factors, developed the lowest stroke and MACE at 3 and 12 months. The paradox of
9
10 high risk of stroke with low LDL-C level could be due to the previous intensive LLT
11
12 and rigid LDL-C control. It is consistent with the previous study that fixed-dose statin
13
14 regimens are less effective than targeting LDL-C levels of 1.8 or 1.4 mmol/l when
15
16 pre-treatment LDL-C levels exceed 4 mmol/L ¹⁶. The target LDL-C of 1.4 mmol/l
17
18 recently advocated in particularly high-risk patients is most effective when pre-
19
20 treatment LDL-C exceeds about 3 mmol/l ¹⁶. The TST trial found that an intensive
21
22 LDL-C lowering target of less than 1.8 mmol/L further reduced the risk of
23
24 cardiovascular events by approximately 20% during a median follow-up of 3.5 years
25
26 in patients with ischaemic stroke within 3 months or a TIA within 15 days, compared
27
28 with the higher target of 2.3–2.8mmol/L.³ 2019 ESC/EAS Guidelines for the
29
30 management of dyslipidaemias set the most aggressive target of less than 1.4 mmol/L
31
32 and a reduction of more than 50% in LDL-C ¹⁷.

33
34
35
36
37
38
39
40
41
42
43 Secondly, our findings proved the safety of the LDL-C level lower than 1.4mmol/L in
44
45 Chinese people: it did not associate with an increased risk of hemorrhagic stroke.

46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Studies of LDL-C and ICH have reported conflicting results. In a twenty-year
epidemiologic study, an excess risk of hemorrhagic stroke was observed in patients
with uncontrolled hypertension and LDL-C <70 mg/dL (1.8mmol/L) ¹⁸. However, in
subgroup analysis of FOURIER trial ¹⁹, among patients with prior stroke, the risk of
hemorrhagic stroke did not increase, even when the median LDL-C decreased from

1
2
3
4 2.4 mmol/L at randomization to 0.8 (0.5–1.2) mmol/L at 48 weeks in the evolocumab
5
6
7 group. All stroke and ischemic stroke were reduced, with no difference in
8
9 hemorrhagic stroke. Meanwhile, in a systematic review and meta-analysis, the higher
10
11 level of LDL-C seemed to be associated with a lower risk of hemorrhagic stroke ²⁰.
12
13 Our study proved the efficacy and safety of that baseline LDL-C of <1.4 mmol/L in
14
15 stroke patients, providing evidence for the first and second prevention strategies.
16
17
18 Thirdly, we described the epidemiological characteristics of LDL-C levels and LLT of
19
20 Chinese stroke patients. Compared to the study conducted in 2013 ²¹, our study
21
22 indicated some progress in blood lipid management in mainland China. In our study,
23
24 about 97% of patients had a medication history of LLT before onset. Compared to the
25
26 LLT rate of 79.6% in 2013, over 90% of patients received LLT during hospitalization
27
28 and at discharge; the LLT compliance was 84.5% at 3 months, 75.6% at 6 months,
29
30 and 64.8% at 12 months. In addition, LDL-C goal achievement for 1.8mmol/L had
31
32 improved mildly, increasing from 27.4% to 35.4%, while LDL-C goal achievement
33
34 for 1.4mmol/L was 17.6% at 12 months. The non-ideal LLT compliance and LDL-C
35
36 control rate might be due to statin intolerance in Asian people, including statin-
37
38 associated myopathy and hemorrhagic stroke ^{22,23}. A meta-analysis indicated that
39
40 statins increase the risk of hemorrhagic stroke in a medication dose-dependent and
41
42 type of index brain vascular injury-dependent manner, while PCSK9 inhibitors do not
43
44 increase hemorrhagic stroke risk²⁴. Thus, statins, rather than low-leveled LDL-C,
45
46 might closely relate to hemorrhagic stroke. PCSK9 inhibitors might be a more
47
48 promising lipid-lowering medication class in patients with an elevated risk of
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 hemorrhagic stroke. In addition, our analysis revealed a significant association
5
6 between LLT at discharge and 3-month outcomes, indicating the importance of early
7
8 LLT.
9

10
11 Fourthly, we did not observe the correlation between the 3-month LDL-C decrease
12
13 amplitude and 12-month outcomes. To analyze the association of 3-month LDL-C
14
15 change with 12-month outcomes, we excluded subjects who reached the end point
16
17 within 3 months, which led to a limited sample size and loss of a considerable amount
18
19 of target events, for most stroke recurrences happened within 3 months²⁵. Another
20
21 critical factor was that we could not adjust some risk factors in the model, such as IL-
22
23 6 level and relevant intracranial artery stenosis (ICAS). They were independent risk
24
25 factors of the residual risk. Although substantially reduced by secondary prevention
26
27 treatment, there was still 8.3% residual risk of 12-month recurrent stroke even in
28
29 patients with persistent adherence to guideline-based secondary stroke prevention²⁶.
30
31

32
33 Our study has several limitations. First, only LLT medication use at the follow-up
34
35 time point was recorded, not the details of use during the whole trial, such as
36
37 continuous use, intermittent use, and the change of dose; thus, lipid-lowering agents
38
39 use at 3 months and 12 months could not represent the actual situation. Second, statin
40
41 use before admission was not recorded in the trial and may confound the results.
42
43

44
45 Details of medication use, such as class, dose, duration, and adherence of lipid-
46
47 lowering agents, did not enter the regression model. Third, there could be some
48
49 undetected confounding factors except for residual risk. Additionally, the trial was
50
51 conducted exclusively on Chinese patients. The finding in this study needs to be
52
53
54
55
56
57
58
59
60

1
2
3
4 further validated in studies with a larger sample size and non-Asian populations.
5

6 **Conclusions**

7
8
9 The LDL-C goal achievement has increased mildly in the stroke and TIA population
10
11 in mainland China and improving of the LDL-C goal achievement is still an essential
12
13 task for secondary prevention of stroke. The lowered baseline LDL-C level was
14
15 significantly associated with a decreased short-and long-term risk of ischemic stroke
16
17 among stroke and TIA patients. LDL-C<1.4mmol/L could be a safe standard for this
18
19 population.
20
21
22
23

24 **Ethics Approval Statement**

25
26
27 The study protocol of the CNSR-III was approved by the ethics committee at Beijing
28
29 Tiantan Hospital (IRB approval number: KY2015-001-01) and all participating
30
31 centers. Every participant provided written informed consent before participation.
32
33
34

35 **Acknowledgement**

36
37 We thank Drs. Feng Sheng and Luan-Luan Sun for their important intellectual
38
39 contributions to the article. We thank all participating hospitals, their physicians, and
40
41 nurses. We appreciate all the patients who took part in the CNSR-III trial.
42
43
44

45 **Competing Interests**

46
47
48 The authors have no conflicts of interest to declare.
49
50

51 **Funding Sources**

52
53
54 This work was supported by the National Key R&D Program of China (No.
55
56 2018YFC1312903), National Natural Science Foundation of China (No. 81870905,
57
58
59
60

1
2
3
4 82071295, 81801139), and Beijing Hospitals Authority Innovation Studio of Young
5
6 Staff Funding Support (Code: 202113).
7
8

9 **Contributorship statement**

10
11 (I) Conception and design: Drs. YY Xu and WQ Chen
12
13

14
15 (II) Administrative support: Drs. X Meng
16
17

18 (III) Provision of study materials or patients: Drs. X Meng, ZX Li
19
20

21 (IV) Collection and assembly of data: Drs. X Meng, XQ Zhao, LP Liu, and YL Wang
22
23

24 (V) Data analysis and interpretation: Drs. MX Wang and YS Pan
25
26

27 (VI) Manuscript writing: All authors.
28
29

30 (VII) Final approval of manuscript: All authors.
31
32

33 **Data sharing statement**

34
35 The datasets used in this study are not publicly available, but these can be provided on
36
37 reasonable request after the approval.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference

1. Wang Y-J, Li Z-X, Gu H-Q, Zhai Y, Jiang Y, Zhao X-Q, Wang Y-L, Yang X, Wang C-J, Meng X, et al. China Stroke Statistics 2019: A Report From the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, the Chinese Stroke Association, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations. *Stroke Vasc. Neurol.* 2020;5:211–239.
2. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KMA, et al. High-dose atorvastatin after stroke or transient ischemic attack. *N. Engl. J. Med.* 2006;355:549–559.
3. Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Béjot Y, Cabrejo L, Cha J-K, Ducrocq G, Giroud M, et al. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. *N. Engl. J. Med.* 2020;382:9.
4. Klijn CJ, Paciaroni M, Berge E, Korompoki E, Kõrv J, Lal A, Putaala J, Werring DJ. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline. *Eur. stroke J.* 2019;4:198–223.

- 1
2
3
4 5. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockcroft KM, Gutierrez J,
5
6 Lombardi-Hill D, Kamel H, Kernan WN, Kittner SJ, Leira EC, et al. 2021
7
8
9 Guideline for the Prevention of Stroke in Patients with Stroke and Transient
10
11 Ischemic Attack: A Guideline From the American Heart Association/American
12
13 Stroke Association. *Stroke*. 2021;52:e364–e467.
14
15
16
- 17 6. Amarenco P, Kim JS, Labreuche J, Giroud M, Lee BC, Mahagne MH,
18
19 Nighoghossian N, Simon T, Steg PG, Touboul PJ, et al. Treat stroke to target
20
21 trial design: First trial comparing two LDL targets in patients with
22
23 atherothrombotic strokes. *Eur. Stroke J*. 2019;4:271–280.
24
25
26
- 27 7. Qureshi AI, Caplan LR. Intracranial atherosclerosis. *Lancet (London,*
28
29 *England)*. 2014;383:984–998.
30
31
32
- 33 8. Wong LKS. Global burden of intracranial atherosclerosis. *Int. J. stroke Off. J.*
34
35 *Int. Stroke Soc*. 2006;1:158–159.
36
37
38
- 39 9. Mok V, Srikanth V, Xiong Y, Phan TG, Moran C, Chu S, Zhao Q, Chu WWC,
40
41 Wong A, Hong Z, et al. Race-ethnicity and cerebral small vessel disease--
42
43 comparison between Chinese and White populations. *Int. J. stroke Off. J. Int.*
44
45 *Stroke Soc*. 2014;9 Suppl A1:36–42.
46
47
48
- 49 10. Wolma J, Nederkoorn PJ, Goossens A, Vergouwen MDI, van Schaik IN,
50
51 Vermeulen M. Ethnicity a risk factor? The relation between ethnicity and large-
52
53 and small-vessel disease in White people, Black people, and Asians within a
54
55 hospital-based population. *Eur. J. Neurol*. 2009;16:522–527.
56
57
58
59
60

- 1
2
3
4 11. Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterol-
5
6 lowering with simvastatin on stroke and other major vascular events in 20536
7
8 people with cerebrovascular disease or other high-risk conditions. *Lancet*
9
10
11
12
13
14
15 12. Oyama K, Giugliano RP, Blazing MA, Park J-G, Tershakovec AM, Sabatine
16
17 MS, Cannon CP, Braunwald E. Baseline Low-Density Lipoprotein Cholesterol
18
19 and Clinical Outcomes of Combining Ezetimibe with Statin Therapy in
20
21
22 IMPROVE-IT. *J. Am. Coll. Cardiol.* 2021;78:1499–1507.
23
24
25
26 13. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy
27
28 SA, Kuder JF, Wang H, Liu T, Wasserman SM, et al. Evolocumab and Clinical
29
30 Outcomes in Patients with Cardiovascular Disease. *N. Engl. J. Med.*
31
32
33
34 2017;376:1713–1722.
35
36
37 14. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand A-C, Stein EA.
38
39 Safety and efficacy of a monoclonal antibody to proprotein convertase
40
41 subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with
42
43 primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. *J.*
44
45
46
47
48
49
50 15. Wang Y, Jing J, Meng X, Pan Y, Wang Y, Zhao X, Lin J, Li W, Jiang Y, Li Z,
51
52 et al. The Third China National Stroke Registry (CNSR-III) for patients with
53
54 acute ischaemic stroke or transient ischaemic attack: design, rationale and
55
56
57
58
59
60 baseline patient characteristics. *Stroke Vasc. Neurol.* 2019;4:158–164.


- 1
2
3
4 16. Soran H, Adam S, Durrington PN. Optimising treatment of hyperlipidaemia:
5
6 Quantitative evaluation of UK, USA and European guidelines taking account
7
8 of both LDL cholesterol levels and cardiovascular disease risk. *Atherosclerosis*.
9
10 2018;278:135–142.
11
12
13
14
15 17. (EAS) TTF for the management of dyslipidaemias of the ESC (ESC) and
16
17 EAS. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid
18
19 modification to reduce cardiovascular risk. *Atherosclerosis*. 2019;290:140–205.
20
21
22
23
24 18. Zhang X, Liu J, Wang M, Qi Y, Sun J, Liu J, Wang Y, Hao Y, Li Y, Zhou M,
25
26 et al. Twenty-year epidemiologic study on LDL-C levels in relation to the risks
27
28 of atherosclerotic event, hemorrhagic stroke, and cancer death among young
29
30 and middle-aged population in China. *J. Clin. Lipidol.* 2018;12:1179-1189.e4.
31
32
33
34
35 19. Giugliano RP, Pedersen TR, Saver JL, Sever PS, Keech AC, Bohula EA,
36
37 Murphy SA, Wasserman SM, Honarpour N, Wang H, et al. Stroke Prevention
38
39 With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor
40
41 Evolocumab Added to Statin in High-Risk Patients With Stable
42
43 Atherosclerosis. *Stroke*. 2020;51:1546–1554.
44
45
46
47
48 20. Wang X, Dong Y, Qi X, Huang C, Hou L. Cholesterol levels and risk of
49
50 hemorrhagic stroke: a systematic review and meta-analysis. *Stroke*.
51
52 2013;44:1833–1839.
53
54
55
56
57
58
59
60

- 1
2
3
4 21. Wang C-J, Wang Y-L, Li Z-X, Wang Y-J. The Management of LDL
5
6 Cholesterol and Predictors of Goal Achievement in Stroke Patients in China: A
7
8 Cross-Sectional Study. *CNS Neurosci. Ther.* 2016;22:577–583.
9
10
11
12 22. Tomlinson B, Chan P, Liu Z-M. Statin Responses in Chinese Patients. *J.*
13
14 *Atheroscler. Thromb.* 2018;25:199–202.
15
16
17
18 23. Tomlinson B, Chan P, Liu Z-M. Statin Intolerance-An Asian Perspective. *J.*
19
20 *Atheroscler. Thromb.* 2020;27:485–488.
21
22
23
24 24. Sanz-Cuesta BE, Saver JL. Lipid-Lowering Therapy and Hemorrhagic Stroke
25
26 Risk: Comparative Meta-Analysis of Statins and PCSK9 Inhibitors. *Stroke.*
27
28 2021;52:3142–3150.
29
30
31
32 25. Coull AJ, Lovett JK, Rothwell PM. Population based study of early risk of
33
34 stroke after transient ischaemic attack or minor stroke: implications for public
35
36 education and organisation of services. *BMJ.* 2004;328:326.
37
38
39
40 26. Pan Y, Li Z, Li J, Jin A, Lin J, Jing J, Li H, Meng X, Wang Y, Wang Y.
41
42 Residual Risk and Its Risk Factors for Ischemic Stroke with Adherence to
43
44 Guideline-Based Secondary Stroke Prevention. *J. stroke.* 2021;23:51–60.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Dose-response-relationship curves

Adjusted odds ratio of events and MACE at 3 months and 12 months according to LDL-C at baseline in patients. (a) stroke at 3 months; (b) ischemic stroke at 3 months; (c) hemorrhagic stroke at 3 months; (d) MACE at 3 months; (e) stroke at 12 months; (f) ischemic stroke at 12 months; (g) hemorrhagic stroke at 12 months; (h) MACE at 12 months. The full line indicates the adjusted hazard ratio and the dashed lines the 95% confidence interval bands. Reference is LDL-C >2.6mmol/L. Data were fitted using a logistic regression model of restricted cubic spline with three knots (the 5th, 50th, 90th percentiles) for LDL-C level, adjusting for potential covariates.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Dose-response-relationship curves

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8
Bias	9	Describe any efforts to address potential sources of bias	9
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	10
		(b) Describe any methods used to examine subgroups and interactions	10
		(c) Explain how missing data were addressed	10
		(d) If applicable, explain how loss to follow-up was addressed	11
		(e) Describe any sensitivity analyses	N/A
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	11
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	11
		(b) Indicate number of participants with missing data for each variable of interest	N/A
		(c) Summarise follow-up time (eg, average and total amount)	12
Outcome data	15*	Report numbers of outcome events or summary measures over time	13

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	13
2			(b) Report category boundaries when continuous variables were categorized	13
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	14
4				
5	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	14
6				
7				
8				
9				
10				
11	Discussion			
12	Key results	18	Summarise key results with reference to study objectives	17
13	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	20
14				
15	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	18
16				
17	Generalisability	21	Discuss the generalisability (external validity) of the study results	18
18				
19				
20				
21	Other information			
22	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	21
23				
24				

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

Lipid Management in Ischemic Stroke or Transient Ischemic Attack in China: Result from China National Stroke Registry III

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-069465.R1
Article Type:	Original research
Date Submitted by the Author:	27-Dec-2022
Complete List of Authors:	Xu, Yuyuan; Beijing Tiantan Hospital, Chen, Weiqi; Beijing Tiantan Hospital Wang, Mengxing; Beijing Tiantan Hospital PAN, YUESONG; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases Li, Zixiao; Beijing Tiantan Hospital, Neurology Liu, Liping; Beijing Tiantan Hospital, Neurology; China National Clinical Research Center for Neurological Diseases, Zhao, Xingquan; Beijing Tiantan Hospital, Neurology Wang, Yilong; Beijing Tiantan Hospital, Department of Neurology Li, Hao; Beijing Tiantan Hospital Wang, Yongjun; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases Meng, Xia; Beijing Tiantan Hospital, Department of Neurology; Capital Medical University
Primary Subject Heading:	Medical management
Secondary Subject Heading:	Neurology, Medical management
Keywords:	Neurology < INTERNAL MEDICINE, Lipid disorders < DIABETES & ENDOCRINOLOGY, Stroke medicine < INTERNAL MEDICINE, Stroke < NEUROLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Lipid Management in Ischemic Stroke or Transient Ischemic Attack in China:**
5
6 **Result from China National Stroke Registry III**
7
8
9

10
11 Yu-Yuan Xu, MD^{a, b}; Wei-Qi Chen, MD^{a, b}; Meng-Xing Wang, PhD^b; Yue-Song
12 Pan, PhD^b; Zi-Xiao Li, MD^{a, b}; Li-Ping Liu, MD^{a, b}; Xing-Quan Zhao, MD^{a, b}; Yi-
13 Long Wang, MD^{a, b}; Hao Li, PhD^b; Yong-Jun Wang, MD^{a, b, c, d}; Xia Meng, MD^{a, b};
14 on behalf of the CNSR-III Investigators
15
16
17
18
19
20
21
22
23

24
25 ^a Department of Neurology, Beijing Tiantan Hospital, Capital Medical University,
26 Beijing, China
27
28

29
30 ^b China National Clinical Research Center for Neurological Diseases, Beijing Tiantan
31 Hospital, Capital Medical University, Beijing, China
32
33

34
35 ^c Advanced Innovation Center for Human Brain Protection, Capital Medical
36 University, Beijing, China
37
38

39
40 ^d Research Unit of Artificial Intelligence in Cerebrovascular Disease, Chinese
41 Academy of Medical Sciences, 2019RU018
42
43
44
45
46
47

48 **Running title:** Lipid management in Ischemic Stroke or TIA
49

50 Correspondence to Dr. Xia Meng: No. 119 South 4th Ring West Road, Fengtai
51 District, Beijing 100070, China. Email: mengxia45@163.com. Phone: +86 10
52 59978245. Fax: +86 10 59973383.
53
54
55
56
57

58 Number of Tables: 7
59
60

1
2
3
4 Number of Figures: 1
5

6
7 Word count: 3469
8
9

10 **Keywords:** low-density lipoprotein cholesterol, lipid-lowering treatment, ischemic
11
12 stroke, second prevention
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Abstract

Background and purpose: Dyslipidaemia is a significant risk factor for ischemic stroke and transient ischemic attack (TIA). The aims of the study were to assess the management of low-density lipoprotein cholesterol (LDL-C) and the goal achievement, as well as to investigate the association between baseline LDL-C level, lipid-lowering treatment (LLT), and stroke recurrence in patients with ischemic stroke or TIA.

Methods: We derived data from the Third China National Stroke Registry (CNSR-III). The primary outcome was a new stroke, LDL-C goal (LDL-C<1.8mmol/L and LDL-C<1.4mmol/L, respectively) achievement rates, and LLT compliance within 3, 6, and 12 months. The associations among the baseline LDL-C level, LLT at discharge, and outcomes were also assessed.

Results: Among the 15,166 patients, over 90% of patients received LLT during hospitalization and 2 weeks after discharge; the LLT compliance was 84.5% at 3 months, 75.6% at 6 months, and 64.8% at 12 months. At 12 months, LDL-C goal achievement rate for 1.8mmol/L and 1.4mmol/L was 35.4% and 17.6%, respectively. LLT at discharge was associated with reduced risk of ischemic stroke recurrence (HR=0.687, 95% CI: 0.480-0.985, p=0.0411) at 3 months. The rate of LDL-C reduction from baseline to 3-month follow-up was not associated with a reduced risk of stroke recurrence or major adverse cardiovascular events (MACE) at 12 months. Patients with baseline LDL-C \leq 1.4mmol/L had a numerically lower risk of stroke, ischemic stroke and MACE at both 3 months and 12 months.

1
2
3
4 **Conclusions:** The LDL-C goal achievement rate has increased mildly in the stroke
5
6 and TIA population in mainland China. Lowered baseline LDL-C level was
7
8 significantly associated with a decreased short- and long-term risk of ischemic stroke
9
10 among stroke and TIA patients. LDL-C<1.4mmol/L might be a safe standard for this
11
12 population.
13
14
15
16
17
18
19

20 **Strengths and limitations of this study**

- 21
22 1. This hospital-based study analyzed the low-density lipoprotein cholesterol (LDL-C)
23
24 levels and lipid-lowering therapy (LLT) in patients with ischemic stroke (IS)/transient
25
26 ischemic attack (TIA) in the general population of mainland China.
27
28
- 29
30 2. The study included the largest sample of IS/TIA patients and recorded detailed
31
32 prognostic characteristics.
33
34
- 35
36 3. The design of the cohort study did not allow for further detailed analysis of lipid-
37
38 lowering medication use, such as dose change and duration.
39
40
- 41
42 4. Some undetected confounding factors, including residual risk, were not able to be
43
44 assessed in this study.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Low-density lipoprotein cholesterol (LDL-C) has been well established as an independent risk factor for ischemic stroke¹. Intensive lipid-lowering treatment (LLT) has been proven to reduce cardiovascular event recurrence in ischemic stroke (IS)/transient ischemic attack (TIA) patients. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study² showed that intensive atorvastatin treatment for five years reduced the risk of stroke recurrence up to 16% (HR 0.84, 95% CI 0.71-0.99; P<0.03) in IS/TIA. Recently, Treat Stroke to Target (TST) study³ also demonstrated that IS/TIA patients who had a target LDL-C level of less than 70 mg/dl (1.8mmol/L) had a lower risk of subsequent cardiovascular events than those who had a target range of 90 to 110 mg/dl (HR 0.78, 95% CI 0.61-0.98; P=0.04). Therefore, European Stroke Organisation (ESO) and American Stroke Association (ASA) both updated the IS/TIA second prevention guideline with a recommendation of LDL-C target goal to be less than 70mg/dl (1.8mmol/L)^{4,5}.

However, there are still clinical questions not thoroughly investigated. Firstly, SPARCL and TST trials are randomized controlled trials conducted mainly in the Caucasian population^{2,6}, whereas studies focusing on the Asian population on lipid management in stroke patients are limited. Since there are more intracranial artery stenosis (ICAS)^{7,8} and cerebral small vessel disease (CSVD) patients in Asia^{9,10}, especially in east Asia, the applicability of the conclusions of these two trials to Asian people should be discreet. Secondly, there are inconsistencies and conflicts about whether the reduced LDL-C level, especially during the acute or subacute phase,

1
2
3
4 could increase the risk of intracranial hemorrhage (ICH). In the SPARCL study,
5
6 subgroup analysis indicated that atorvastatin treatment might increase the risk of ICH,
7
8
9 which led to a big concern for statin usage during the acute phase of IS/TIA ¹¹. In
10
11 contrast, the TST study showed that the incidence of ICH did not differ significantly
12
13 between the lower- and higher-target groups ³. Thirdly, with emerging evidence from
14
15 non-statin therapies such as IMPROVE-IT ¹², FOURIER ¹³, and ODYSSEY ¹⁴, a lower
16
17 LDL-C target of less than 1.4mmol/L or even 1.0mmol/L has been recommended for
18
19 adoption as international guidelines. However, the benefits of a lower LDL-C target
20
21 lower than 1.8mmol/L have not been investigated.

22
23
24
25
26
27 The Third China National Stroke Registry (CNSR-III) is one of the world's most
28
29 extensive IS/TIA cohort studies and it includes comprehensive medical histories,
30
31 centralized the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification
32
33 judication, and follow-up outcomes. We aimed to collect data from CNSR-III to
34
35 investigate the China's current lipid management practices and the associations
36
37 between LDL-C level, LLT, and stroke recurrence in ischemic stroke or TIA patients.
38
39
40
41

42 **Methods**

43 **Study design and participants**

44
45
46
47
48
49
50 The study was based on the CNSR-III database. The CNSR-III is a nationwide
51
52 clinical registry of ischemic stroke or transient ischemic attack (TIA) based on
53
54 etiology, imaging, and biological markers in China from August 2015 to March 2018
55
56
57
58 ¹⁵. 201 participating hospitals were selected in China, and 15,166 patients were
59
60

1
2
3
4 eligible and had complete information at baseline. The total 15,166 patients were
5
6 included in the analysis.
7

8
9 Among all the clinical centers included in CNSR-III, 169 centers voluntarily
10
11 participated in the prespecified blood biomarker substudy, with all the patients at
12
13 these centers participating in the biomarker substudy. Such patients provided a
14
15 separate written informed consent form that included their consent for blood sample
16
17 collection and further study of biomarkers.
18
19

20
21 The study protocol of the CNSR-III was approved by the ethics committee at Beijing
22
23 Tiantan Hospital (IRB approval number: KY2015-001-01) and all participating
24
25 centres. Every participant provided written informed consent before participation.
26
27
28

29 30 31 **Data Collection and Management** 32

33
34 Patient information, including demographics, risk factors, comorbidities, medications,
35
36 selected laboratory tests, and hospital-level characteristics, were collected
37
38 systematically during hospitalization and at discharge by trained research coordinators
39
40 at each participating hospital. National Institutes of Health Stroke Scale (NIHSS)
41
42 score at admission, and ischemic stroke recurrence, composite vascular event, and
43
44 modified Rankin Scale (mRS) at 3 months and 1 year after stroke onset were also
45
46 collected.
47
48
49

50
51 Venous blood samples were collected from fasting patients within 24 hours from
52
53 admission. Serum specimens were extracted, aliquoted, and transported through the
54
55 cold chain to the central laboratory in Beijing Tiantan Hospital and stored at -80°C.
56
57
58
59
60

1
2
3
4 LDL-C measurements were centrally and blindly assayed by enzymatic method on the
5
6 Cobas 8000 analyzer c702 module (Roche Diagnostics, Mannheim, Germany).
7
8
9

10 **Follow-Up and Clinical Outcome Evaluations**

11
12
13

14 Patients were followed up through face-to-face interviews at 3 months and by
15
16 telephone interviews at 6 and 12 months by trained research coordinators who
17
18 followed a standardized interview protocol. Information collected at each follow-up
19
20 included cardio- and cerebrovascular events, all causes of death, and medications use.
21
22 Vascular events were confirmed with the treating hospital, and death was either
23
24 confirmed based on a death certificate issued by the attended hospital or the local civil
25
26 registry.
27
28
29
30

31
32 The primary outcome was a new stroke (defined as a new neurological deficit lasting
33
34 more than 24 hours or re-hospitalization with a diagnosis of ischemic stroke,
35
36 intracerebral hemorrhage, or subarachnoid hemorrhage), LDL-C goal (LDL-
37
38 C<1.4mmol/L, and LDL-C<1.8mmol/L, respectively) achievement rates and LLT
39
40 compliance in China within 3, 6, and 12 months. The secondary outcomes included
41
42 major adverse cardiovascular events (including stroke, myocardial infarction, or
43
44 vascular death) and all caused death at 3 months and 12 months.
45
46
47
48
49

50 All reported efficacy and safety outcomes were verified by a central independent
51
52 adjudication committee blinded to study treatment assignments and baseline LDL-C
53
54 level.
55
56
57
58
59
60

1
2
3
4 Patients were categorized into four groups according to the baseline LDL-C levels and
5
6 lipid-lowering treatment during hospitalization and after discharge: LDL-
7
8 $C \leq 1.4 \text{ mmol/L}$, $1.4 \text{ mmol/L} < \text{LDL-C} \leq 1.8 \text{ mmol/L}$, $1.8 \text{ mmol/L} < \text{LDL} \leq 2.6 \text{ mmol/L}$,
9
10 $\text{LDL} > 2.6 \text{ mmol/L}$.
11
12

13
14 LLT compliance was defined as the continuation of LLT medication from discharge
15
16 to 3, 6, or 12 months after the onset of symptoms. Patients assigned to LLT at
17
18 discharge but later discontinuing LLT at any follow-up point within 3, 6, or 12
19
20 months were considered “non-persistent”. Patients were considered persistent if they
21
22 discontinued one medication but replaced it with another statin medication that they
23
24 continued taking through 3, 6, or 12 months after enrollment.
25
26
27
28
29

30 31 **Statistical analysis**

32
33
34 Baseline variables were presented as median with interquartile range (IQR) for
35
36 continuous variables and percentages for categorical variables.
37
38

39
40 To analyze the association of baseline LDL-C levels and outcomes, we only included
41
42 those subjects who provided 3-month or 12-month bio-sample. Univariate and
43
44 multivariate Cox proportional hazard regression models were used. The model
45
46 included the following covariates: age, sex, education, current smoking, heavy
47
48 drinking, medical history, stroke severity on the NIHSS, history of stroke, history of
49
50 diabetes, and history of hypertension. Adjusted hazard ratios (HRs) with 95%
51
52 confidence intervals (CIs) were calculated. The dose-response-relationship curves
53
54
55
56
57
58 were also presented.
59
60

1
2
3
4 To analyze the effect of discharge LLT on outcomes, we excluded subjects who
5
6 reached the end point (stroke recurrence or MACE, death, and loss to follow-up)
7
8 during hospitalization. We performed a univariate model and multivariate analysis by
9
10 adjusting for age, sex, education, current smoking, heavy drinking, medical history,
11
12 stroke severity on the NIHSS, history of stroke, history of diabetes, and history of
13
14 hypertension.
15
16
17

18
19 In addition, to analyze the association of 3-month LDL-C change with stroke
20
21 recurrence and MACE within 12 months, we excluded subjects who reached the end
22
23 point (stroke recurrence or MACE, death, and loss to follow-up) within 3 months.
24
25

26
27 All statistical analyses in the study were performed by SAS 9.4 software. All
28
29 statistical analysis adopted a two-sided test which was performed at a 5% significance
30
31 level.
32
33
34

35 36 **Patient and Public Involvement**

37
38 This registry study was designed and conducted without patient and public
39
40 involvement. Our results will be disseminated to the public through publication in this
41
42 journal.
43
44
45

46 47 48 **Results**

49 50 51 52 **Characteristics of study participants**

53
54
55 From August 2015 to March 2018, a total of 15166 patients with acute stroke and TIA
56
57 were recruited to the CNSR-III trial and entered our final analysis. The average age of
58
59
60

patients was 62.2 ± 11.3 years, 31.7% of patients were women, 14,146 (93.3%) had an index event of stroke, and 1020 (6.7%) had a TIA¹⁵.

Baseline LDL-C levels

There were 10,738 patients in LDL-C analysis set: 1,407 (13.1%), 1,636 (15.2%), 3,655 (34.0%), and 4,040 (37.6%) patients with the baseline LDL-C ≤ 1.4 mmol/L, 1.4–1.8 mmol/L, 1.8–2.6 mmol/L, ≥ 2.6 mmol/L, respectively (Table 1).

Table 1. Baseline Characteristics for the LDL-C analysis set

Variables	LDL ≤ 1.4 mmol/L N=1407	1.4 < LDL ≤ 1.8 mmol/L N=1636	1.8 < LDL ≤ 2.6 mmol/L N=3655	LDL > 2.6 mmol/L N=4040	P Value*
Women, n (%)	378 (26.9)	439 (26.8)	1057 (28.9)	1517 (37.6)	<0.001
Mean age, years (SD)	60.8 \pm 11.9	62.4 \pm 11.3	62.2 \pm 11.3	62.8 \pm 11.1	<0.001
Ethnicity (non-Han), n (%)	30 (2.1)	49 (3.0)	122 (3.3)	104 (2.6)	0.07
Current smoker, n (%)	435 (30.9)	525 (32.1)	1239 (33.9)	1198 (29.7)	<0.001
Heavy drinker, n (%)*	185 (13.2)	210 (12.8)	545 (14.9)	589 (14.6)	0.12
Triglycerides (IQR)	1.3 (0.9-1.9)	1.3 (1.0-1.8)	1.3 (1.0-1.8)	1.5 (1.1-2.0)	<0.001
TC, mmol/L	2.7 (2.4-3.1)	3.2 (3.0-3.5)	3.8 (3.5-4.1)	4.9 (4.5-5.5)	<0.001
HDL-C, mmol/L	0.8 (0.7-1.0)	0.9 (0.8-1.1)	0.9 (0.8-1.1)	1.0 (0.8-1.2)	<0.001
LDL-C, mmol/L	1.2 (1.0-1.3)	1.6 (1.5-1.7)	2.2 (2.0-2.4)	3.2 (2.9-3.8)	<0.001
BMI	24.4 (22.5-26.4)	24.5 (22.7-26.6)	24.4 (22.5-26.4)	24.5 (22.7-26.7)	0.06
Systolic pressure, mmHg	145.0 (132.5-160.0)	146.5 (133.0-161.0)	148.5 (135.0-163.5)	150.0 (136.0-166.5)	<0.001
Medical history, n (%)					
Ischemic stroke	369 (26.2)	429 (26.2)	715 (19.6)	748 (18.5)	<0.001
TIA	44 (3.1)	46 (2.8)	115 (3.6)	102 (2.5)	0.38
Coronary heart diseases	147 (10.5)	193 (11.8)	366 (10.0)	449 (11.1)	0.20
Atrial fibrillation	93 (6.6)	124 (7.6)	272 (7.4)	257 (6.4)	0.19
Hypertension	897 (63.8)	1045 (63.9)	2295 (62.8)	2516 (62.3)	0.62
Diabetes mellitus	386 (27.4)	394 (24.1)	824 (22.5)	960 (23.8)	0.004
Hypercholesterolemia	119 (8.5)	120 (7.3)	302 (8.3)	341 (8.4)	0.56
NIHSS at admission, median (IQR)	3.0 (1.0-6.0)	3.0 (1.0-6.0)	3.0 (1.0-6.0)	3.0 (1.0-6.0)	<0.001
NIHSS 0–3	743 (52.8)	914 (55.9)	1974 (54.0)	2073 (51.3)	0.009
NIHSS ≥ 4	664 (47.2)	722 (44.1)	1681 (46.0)	1967 (48.7)	
mRS (IQR)	0 (0-1.0)	0 (0-1.0)	0 (0-1.0)	0 (0-0)	<0.001
Stroke subtype, n (%)					
LAA	303 (21.5)	390 (23.8)	933 (25.5)	1092 (27.0)	0.0095
CE	81 (5.8)	96 (5.9)	251 (6.9)	256 (6.3)	
SAO	312 (22.2)	359 (21.9)	740 (20.3)	819 (20.3)	
Other	21 (1.5)	16 (1.0)	38 (1.0)	47 (1.2)	
Unknown	690 (49.0)	775 (47.4)	1693 (46.3)	1826 (45.2)	
Prestroke antiplatelet therapy, n (%)	1357 (97.4)	1569 (97.1)	3504 (96.7)	3894 (97.0)	0.57

Prestroke LLT, n (%)	1359 (97.6)	1558 (96.4)	3498 (96.5)	3897 (97.1)	0.15
Statin, n (%)	1355 (97.3)	1556 (96.3)	3491 (96.3)	3887 (96.9)	0.27

TC: total cholesterol. HDL-C: high-density lipoprotein cholesterol. LDL-C: low-density lipoprotein cholesterol. BMI: body mass index. TIA: transient ischemic attack. NIHSS: National Institutes of Health Stroke Scale. mRS: modified Rankin Scale. LAA: large artery atherosclerosis. CE: cardiogenic embolism. SAO: small artery occlusion. LLT: lipid-lowering therapy.

Patients in the lower baseline LDL-C level group (≤ 1.4 mmol/L) were more likely to be younger ($p < 0.0001$) and had a greater prevalence of cardiovascular risk factors (previous stroke, hypertension, hypercholesterolemia, diabetes mellitus, and history of stroke) ($p < 0.0001$) and lower levels of triglycerides, total cholesterol and high-density lipoprotein (HDL) ($p < 0.0001$). About 97% of the patients had a history of antiplatelet and lipid-lowering therapy, and the rates showed no difference among the four baseline LDL-C groups.

Association between baseline LDL-C levels and outcomes at 3 months and 12 months

There were 656 (6.11%) new stroke occurrences at 3 months and 1037 (9.66%) at 12 months (Table 2).

Table 2. Association between baseline LDL-C levels and outcomes at 3 months and 12 months

	Total	Events (n%)	HR (95% CI) Unadjusted	P value	HR (95% CI) Adjusted	P value
3 months						
Stroke recurrence						
LDL ≤ 1.4 mmol/L	1407	69 (4.9)	0.72 (0.55-0.94)	0.01	0.74 (0.57-0.97)	0.03
1.4<LDL ≤ 1.8 mmol/L	1636	95 (5.8)	0.85 (0.68-1.08)	0.18	0.89 (0.70-1.12)	0.32
1.8<LDL ≤ 2.6 mmol/L	3655	219 (6.0)	0.88 (0.74-1.05)	0.17	0.91 (0.76-1.08)	0.28
LDL>2.6mmol/L	4040	273 (6.8)	Reference	-	Reference	-
Ischemic stroke						
LDL ≤ 1.4 mmol/L	1407	65 (4.6)	0.72 (0.55-0.95)	0.02	0.74 (0.56-0.98)	0.03
1.4<LDL ≤ 1.8 mmol/L	1636	88 (5.4)	0.84 (0.66-1.07)	0.16	0.87 (0.68-1.11)	0.27
1.8<LDL ≤ 2.6 mmol/L	3655	201 (5.5)	0.86 (0.72-1.04)	0.11	0.89 (0.74-1.07)	0.22
LDL>2.6mmol/L	4040	257 (6.4)	Reference	-	Reference	-
Hemorrhagic stroke						
LDL ≤ 1.4 mmol/L	1407	4 (0.3)	0.52 (0.18-1.51)	0.23	0.55 (0.19-1.61)	0.28

1.4<LDL≤1.8mmol/L	1636	9 (0.6)	1.01 (0.46-2.19)	0.98	1.03 (0.47-2.26)	0.93
1.8<LDL≤2.6mmol/L	3655	20 (0.6)	1.00 (0.55-1.84)	0.99	0.93 (0.50-1.73)	0.82
LDL>2.6mmol/L	4040	22 (0.5)	Reference	-	Reference	-
MACE						
LDL≤1.4mmol/L	1407	71 (5.1)	0.72 (0.56-0.94)	0.01	0.75 (0.57-0.97)	0.03
1.4<LDL≤1.8mmol/L	1636	100 (6.1)	0.88 (0.70-1.10)	0.27	0.91 (0.72-1.15)	0.42
1.8<LDL≤2.6mmol/L	3655	231 (6.3)	0.91 (0.77-1.08)	0.29	0.93 (0.78-1.11)	0.43
LDL>2.6mmol/L	4040	279 (6.9)	Reference	-	Reference	-
12 months						
Stroke recurrence						
LDL≤1.4mmol/L	1407	114 (8.1)	0.76 (0.62-0.93)	0.009	0.77 (0.62-0.95)	0.01
1.4<LDL≤1.8mmol/L	1636	158 (9.7)	0.91 (0.76-1.08)	0.30	0.92 (0.76-1.10)	0.36
1.8<LDL≤2.6mmol/L	3655	339 (9.7)	0.87 (0.76-1.01)	0.06	0.89 (0.77-1.03)	0.12
LDL>2.6mmol/L	4040	426 (10.5)	Reference	-	Reference	-
Ischemic stroke						
LDL≤1.4mmol/L	1407	102 (7.6)	0.72 (0.58-0.90)	0.004	0.73 (0.59-0.91)	0.005
1.4<LDL≤1.8mmol/L	1636	145 (8.9)	0.89 (0.73-1.07)	0.22	0.90 (0.74-1.09)	0.27
1.8<LDL≤2.6mmol/L	3655	304 (8.3)	0.83 (0.72-0.97)	0.02	0.86 (0.74-1.00)	0.04
LDL>2.6mmol/L	4040	400 (9.9)	Reference	-	Reference	-
Hemorrhagic stroke						
LDL≤1.4mmol/L	1407	12 (0.9)	0.96 (0.50-1.84)	0.89	0.97 (0.50-1.88)	0.93
1.4<LDL≤1.8mmol/L	1636	15 (0.9)	1.03 (0.56-1.87)	0.94	1.02 (0.56-1.88)	0.95
1.8<LDL≤2.6mmol/L	3655	37 (1.0)	1.13 (0.72-1.80)	0.59	1.10 (0.69-1.75)	0.69
LDL>2.6mmol/L	4040	36 (0.9)	Reference	-	Reference	-
MACE						
LDL≤1.4mmol/L	1407	119 (8.5)	0.76 (0.62-0.93)	0.008	0.77 (0.62-0.94)	0.01
1.4<LDL≤1.8mmol/L	1636	170 (10.4)	0.94 (0.79-1.12)	0.47	0.94 (0.79-1.13)	0.50
1.8<LDL≤2.6mmol/L	3655	363 (9.9)	0.90 (0.78-1.03)	0.13	0.91 (0.79-1.05)	0.20
LDL>2.6mmol/L	4040	444 (11.0)	Reference	-	Reference	-

LDL-C: low-density lipoprotein cholesterol. MACE: major adverse cardiovascular events.

Compared with patients with other LDL-C level subgroups, the patients with LDL-C ≤1.4mmol/L had a numerically lower risk of stroke (HR=0.742, 95% CI: 0.568-0.970, p=0.0291), ischaemic stroke (HR=0.741, 95% CI: 0.562-0.976, p=0.0329) and MACE (HR=0.746, 95% CI: 0.573-0.972, p=0.0297) at 3 months. Similar results were found for the outcome of stroke (HR=0.767, 95% CI: 0.622-0.946, p=0.0131), ischaemic stroke (HR=0.731, 95% CI: 0.587-0.911, p=0.0052) and MACE (HR=0.766, 95% CI: 0.624-0.940, p=0.0106) at 12 months after the initial event. Lower baseline LDL-C level was not associated with an increased risk of hemorrhagic stroke at either 3 months or 12 months (**Table 2**). Using a Cox regression model with restricted cubic

splines, a strong association was also found between baseline LDL-C level and risk of stroke, ischemic stroke, hemorrhagic stroke, and MACE (**Figure 1**).

Lipid-lowering management, LLT compliance, and association of discharge LLT and outcomes

LLT management and compliance of the included patients during hospitalization, at discharge, 3 months, 6 months, and 12 months after the initial event were shown in

Table 3.

Table 3. Lipid-lowering Treatment (LLT) and the compliance of patients in

CNSR-III

	Hospitalization	Discharge	3 months	6 months	12 months
Non LLT	547 (3.6)	1300 (8.6)	2590 (17.4)	3007 (22.4)	3754 (26.0)
LLT	14506 (96.4)	13831 (91.4)	12271 (82.6)	11726 (77.6)	10682 (74.0)
Compliance					
Non-Persistent	/	/	2147 (15.5)	3382 (24.5)	4863 (35.2)
Persistent	/	/	11684 (84.5)	10449 (75.6)	8968 (64.8)

Over 90% of patients received LLT during hospitalization and for 2 weeks after discharge. The LLT compliance was 84.5% at 3 months, 75.6% at 6 months, and 64.8% at 12 months. The drug regimens of LLT for the patients in CNSR-III at 3 months, 6 months, and 12 months were shown in **Table 4**.

Table 4. Lipid-lowering Treatment of the included patients in CNSR-III at 3-month, 6-month, 12-month follow-up (n=15166)

Treatment	Patients with statins, N (%)				
	Hospitalization	Discharge	3 months	6 months	12 months
Atorvastatin	10527 (69.41)	9851 (64.95)	8656 (57.08)	8228 (54.25)	7470 (49.25)
<40mg	7442 (70.71)	8770 (89.03)	8284 (95.7)	7963 (96.78)	7269 (97.35)
≥40mg	3083 (29.29)	1081 (10.97)	372 (4.3)	265 (3.22)	198 (2.65)
Rosuvastatin	3546 (23.38)	3395 (22.39)	2903 (19.14)	2779 (18.32)	2489 (16.41)
<20mg	2876 (81.15)	2983 (87.86)	2650 (91.38)	2536 (91.29)	2313 (92.93)
≥20mg	668 (18.85)	412 (12.14)	250 (8.62)	242 (8.71)	176 (7.07)
Simvastatin	272 (1.79)	239 (1.58)	390 (2.57)	411 (2.71)	444 (2.93)
Pravastatin	166 (1.09)	165 (1.09)	137 (0.9)	128 (0.84)	100 (0.66)

lovastatin	25 (0.16)	24 (0.16)	33 (0.22)	33 (0.22)	30 (0.2)
Fluvastatin	54 (0.36)	53 (0.35)	52 (0.34)	43 (0.28)	47 (0.31)
Pravastatin	61 (0.40)	78 (0.51)	70 (0.46)	64 (0.42)	61 (0.4)

Compared with the non-discharge LLT group, LLT at discharge was associated with reduced risk of ischemic stroke (HR=0.65, 95% CI: 0.45-0.94, p=0.02) and stroke recurrence (HR=0.69, 95% CI: 0.48-0.99, p=0.04) at 3 months (Table 5).

Table 5. The association of Discharge Lipid Lowering Therapy (LLT) and outcomes

	Total	Events, (n%)	HR (95% CI) Unadjusted	P value	HR (95% CI) Adjusted	P value
3 months						
Stroke recurrence						
Discharge LLT	13248	269 (2.0%)	0.68(0.48-0.96)	0.03	0.69(0.48-0.99)	0.04
Non discharge LLT	1181	35 (3.0%)	Reference		Reference	
Ischemic stroke						
Discharge LLT	13263	245 (1.9%)	0.68(0.47-0.98)	0.04	0.65(0.45-0.94)	0.02
Non discharge LLT	1188	32 (2.7%)	Reference		Reference	
Hemorrhagic stroke						
Discharge LLT	13740	31 (0.2%)	0.71(0.25-2.01)	0.52	1.19(0.36-3.98)	0.78
Non discharge LLT	1266	4 (0.3%)	Reference		Reference	
MACE						
Discharge LLT	13248	299 (2.3%)	0.71(0.51-1.003)	0.052	0.74(0.52-1.04)	0.08
Non discharge LLT	1181	37 (3.1%)	Reference		Reference	
12 months						
Stroke recurrence						
Discharge LLT	13248	758 (5.7%)	0.88(0.7-1.12)	0.30	0.89(0.7-1.14)	0.36
Non discharge LLT	1181	75 (6.4%)	Reference		Reference	
Ischemic stroke						
Discharge LLT	13263	683 (5.2%)	0.87(0.68-1.11)	0.26	0.86(0.67-1.10)	0.23
Non discharge LLT	1188	69 (5.8%)	Reference		Reference	
Hemorrhagic stroke						
Discharge LLT	13740	86 (0.6%)	0.97(0.47-2.00)	0.94	1.23(0.56-2.69)	0.60
Non discharge LLT	1266	8 (0.6%)	Reference		Reference	
MACE						
Discharge LLT	13248	838 (6.3%)	0.94(0.75-1.19)	0.60	0.96(0.76-1.21)	0.72
Non discharge LLT	1181	78(6.6%)	Reference		Reference	

Patients who reached the end point (stroke recurrence or MACE, death, and loss to follow-up) during hospitalization were excluded.

LDL-C goal achievement and the association of LDL-C changes (from baseline to 3 months) with outcomes at 12 months

The overall blood lipid levels at baseline and at 3-month, and 12-month follow-up were shown in **Table 6**. LDL-C goal of 1.8mmol/L was achieved by 28.3% of patients at baseline, 46.7% at 3 months, and 35.4% at 12 months; LDL-C goal of 1.4mmol/L was achieved by 13.1% of patients at baseline, 25.6% at 3 months, and 17.6% at 12 months.

Table 6. Blood Lipid Level of the included patients at baseline, 3 months and 1 year in CNSR-III

Lipids, mmol/L	Baseline N=10738	3M N=6034	12M N=4899
Median triglycerides (IQR), mmol/L	1.37(1.03-1.87)	1.32(0.98-1.81)	1.46(1.04-2.16)
Total cholesterol, mmol/L	3.97(3.31-4.72)	3.74(3.13-4.54)	3.92(3.25-4.76)
HDL-C, mmol/L	0.93(0.78-1.12)	1.02(0.86-1.21)	0.99(0.79-1.2)
LDL-C, mmol/L	2.31(1.73-2.97)	1.87(1.39-2.55)	2.14(1.57-2.87)
LDL <1.4mmol/L, n (%)	1407 (13.1)	1547 (25.6)	862 (17.6)
1.4 < LDL ≤1.8mmol/L, n (%)	1636 (15.2)	1272 (21.1)	872 (17.8)
1.8 < LDL ≤2.6mmol/L, n (%)	3655 (34.0)	1785 (29.6)	1533 (31.3)
LDL >2.6mmol/L, n (%)	4040 (37.6)	1430 (23.7)	1632 (33.3)

HDL-C: high-density lipoprotein cholesterol. LDL-C: low-density lipoprotein cholesterol.

We did not find any significant association between the LDL-C reduction rate from baseline to 3-month follow-up and the risk of stroke and MACE at 12 months (**Table 7**).

Table 7. Association of LDL-C changes (from baseline to 3 months) with outcomes at 12 months

Percentage of LDL level decrease (compared to baseline)	Total	Events, (n%)	HR (95% CI) unadjusted	P value	HR (95% CI) adjusted	P value
12 months						
Stroke recurrence*						
<30%, n (%)	3526	137 (3.9)	1.48 (0.92-2.39)	0.11	1.42 (0.87-2.30)	0.16
30-50%, n (%)	1146	45 (3.9)	1.50 (0.88-2.56)	0.14	1.44 (0.84-2.47)	0.19
>50%, n (%)	718	19 (2.7)	Reference		Reference	
MACE‡						

<30%, n (%)	3526	149 (4.2)	1.46 (0.92-2.20)	0.11	1.39 (0.88-2.21)	0.16
30-50%, n (%)	1146	47 (4.1)	1.41 (0.84-2.36)	0.19	1.36 (0.81-2.28)	0.24
>50%, n (%)	718	21 (2.9)	Reference		Reference	

* Patients with stroke recurrence, death, and loss to follow-up within 3 months were excluded.

‡ Patients with MACE, death, and loss to follow-up within 3 months were excluded.

Discussion

This national hospital-based study described the current LDL-C level and LLT of IS/TIA patients in the real world. We described the LLT management and LDL-C goal achievement. We also found that a lowered baseline LDL-C level was associated with a decreased risk of new ischemic stroke and MACE at both 3 months and 12 months after the initial event, without an increased risk of intracranial hemorrhage. In addition, LLT at discharge was associated with a reduced risk of CV events at 3 and 12 months. Given the large sample size of LDL-C levels of IS/TIA patients and comprehensive prognostic characteristics recorded, these findings may have important clinical implications.

Firstly, LDL-C of 1.4 mmol/l might be a reasonable target for the high-risk population. Our study indicated that the LDL \leq 1.4 mmol/L group, with the highest risk factors, had the lowest stroke and MACE rates at 3 and 12 months. The paradox of high risk of stroke with low LDL-C level could be due to the previous intensive LLT and rigid LDL-C control. It is consistent with the previous study that fixed-dose statin regimens are less effective than targeting LDL-C levels of 1.8 or 1.4 mmol/l when pre-treatment LDL-C levels exceed 4 mmol/L¹⁶; and the target of 1.4 mmol/l recently advocated in particularly high-risk patients is most effective when pre-treatment LDL-C exceeds 3 mmol/l¹⁶. In addition, 2019 ESC/EAS Guidelines for the management of dyslipidaemias set the most aggressive target of less than 1.4 mmol/L

1
2
3
4 and a reduction of more than 50% in LDL-C ¹⁷.

5
6 Secondly, our findings suggested that the safety of the LDL-C ≤ 1.4 mmol/L at least in
7
8 Chinese population, because this level was not associate with an increased risk of
9
10 hemorrhagic stroke. Studies of LDL-C and ICH have reported conflicting results. In a
11
12 twenty-year epidemiologic study, an excess risk of hemorrhagic stroke was observed
13
14 in patients with uncontrolled hypertension and LDL-C < 70 mg/dL (1.8 mmol/L) ¹⁸.
15
16 However, in a subgroup analysis of FOURIER trial ¹⁹, among patients with prior
17
18 stroke, the risk of hemorrhagic stroke did not increase, even when the median LDL-C
19
20 decreased from 2.4 mmol/L at randomization to 0.8 (0.5–1.2) mmol/L at 48 weeks in
21
22 the evolocumab group. All stroke and ischemic stroke rates were reduced, and the rate
23
24 of hemorrhagic stroke was not significantly changed. Meanwhile, in a systematic
25
26 review and meta-analysis, the higher level of LDL-C tended to be associated with a
27
28 lower risk of hemorrhagic stroke ²⁰. Thus, our study indicated the efficacy and safety
29
30 of the baseline LDL-C of < 1.4 mmol/L in IS/TIA patients, providing evidence for the
31
32 first and second prevention strategies.
33
34

35
36 Thirdly, we described the epidemiological characteristics of Chinese IS/TIA patients
37
38 in relation to their LDL-C levels and LLT. Compared to the study conducted in 2013
39
40 ²¹, our study indicated some progress in blood lipid management in mainland China.
41
42 Notably, about 97% of patients had LLT medication history prior to the entry into our
43
44 study. Also, compared to the LLT rate of 79.6% in 2013, over 90% of patients in our
45
46 cohort received LLT during hospitalization and at discharge; the LLT compliance was
47
48 84.5% at 3 months, 75.6% at 6 months, and 64.8% at 12 months. In addition, LDL-C
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 goal achievement for 1.8mmol/L had improved mildly, from 27.4% to 35.4%, and
5
6 LDL-C goal achievement for 1.4mmol/L was 17.6% at 12 months. The less than
7
8 perfect LLT compliance and LDL-C control rate might be due to statin intolerance in
9
10 Asian people, including statin-associated myopathy and hemorrhagic stroke^{22,23}. An
11
12 earlier meta-analysis indicated that statins increase the risk of hemorrhagic stroke in a
13
14 medication dose-dependent and type of index brain vascular injury-dependent
15
16 manner, while PCSK9 inhibitors do not increase hemorrhagic stroke risk²⁴. Thus,
17
18 statins, rather than low-level of LDL-C, might closely relate to the risk of
19
20 hemorrhagic stroke. Accordingly, PCSK9 inhibitors might be a more promising lipid-
21
22 lowering medication class in patients with an elevated risk of hemorrhagic stroke. In
23
24 addition, our analysis revealed a significant association between LLT at discharge and
25
26 3-month outcomes, indicating the importance of early LLT implementation.
27
28 Fourthly, we did not observe the correlation between the 3-month LDL-C decrease
29
30 amplitude and 12-month outcomes. To analyze the association of 3-month LDL-C
31
32 change with 12-month outcomes, we excluded subjects who reached the end point
33
34 within 3 months, which led to a reduction of our sample size and a loss of a
35
36 considerable number of target events, for most stroke recurrences occurred within 3
37
38 months²⁵. Another critical factor was that we could not adjust some risk factors in the
39
40 model, such as IL-6 level or the evidence of relevant intracranial artery stenosis
41
42 (ICAS), which were independent risk factors of the residual risk. Although
43
44 substantially reduced by secondary prevention treatment, there was still 8.3% residual
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 risk of 12-month recurrent stroke even in patients with persistent adherence to
5
6 guideline-based secondary stroke prevention ²⁶.
7
8

9 Our study has several limitations. First, only LLT medication use at the follow-up
10
11 time points was recorded, whereas additional details of use during the whole trial,
12
13 such as continuous use, intermittent use, and the dose changes were not subjected to
14
15 specific analysis. Thus, lipid-lowering agents use at 3 months and 12 months provided
16
17 only a partial picture of the course of medication during the trial. Second, statin use
18
19 before admission was not recorded in the trial which may confound the results.
20
21 Furthermore, details of medication use, such as class, dose, duration, and adherence of
22
23 lipid-lowering agents, did not enter the regression model. Third, there could be some
24
25 undetected confounding factors in addition to those regarded as the residual risk.
26
27 Forth, the use of dual antiplatelet therapy may reduce the risk of a 3-month recurrence
28
29 of stroke for more than half of the patients presented with an initial NIHSS score of
30
31 ≤ 3 . Fifth, the trial was conducted exclusively on Chinese patients. The finding in this
32
33 study needs to be further validated in studies with a larger sample size and non-Asian
34
35 populations.
36
37
38
39
40
41
42
43
44

45 **Conclusions**

46
47 The LDL-C goal achievement has increased mildly in the stroke and TIA population
48
49 in mainland China, and its further improvement is still an essential task for secondary
50
51 prevention of stroke. The lowered baseline LDL-C level was significantly associated
52
53 with a decreased short-and long-term risk of ischemic stroke among stroke and TIA
54
55 patients. LDL-C < 1.4 mmol/L could be a safe standard for this population.
56
57
58
59
60

Ethics Approval Statement

The study protocol of the CNSR-III was approved by the ethics committee at Beijing Tiantan Hospital (IRB approval number: KY2015-001-01) and all participating centers. Every participant provided written informed consent before participation.

Acknowledgement

We thank Dr. Feng Sheng for his important intellectual contributions to the article.

We thank all participating hospitals, their physicians, and nurses. We appreciate all the patients who took part in the CNSR-III trial.

Competing Interests

The authors have no conflicts of interest to declare.

Funding Sources

This work was supported by the National Key R&D Program of China (No. 2018YFC1312903), National Natural Science Foundation of China (No. 81870905, 82071295, 81801139), and Beijing Hospitals Authority Innovation Studio of Young Staff Funding Support (Code: 202113).

Contributorship statement

Drs. YY Xu and X Meng conceived and designed the study. Drs. X Meng and YJ Wang served as scientific advisors. Drs. X Meng, ZX Li, Hao Li, and YJ Wang critically reviewed the study proposal. Drs. X Meng, XQ Zhao, LP Liu, and YL Wang collected and assembled the data. Drs. MX Wang and YS Pan did statistical analyses. Drs. YY Xu and WQ Chen interpreted the data. Drs. YY Xu drafted the manuscript and did the language editing. Dr. X Meng is responsible for the overall content as

1
2
3
4 guarantor. All the authors approved the final manuscript as submitted and agree to be
5
6 accountable for all aspects of the work.
7
8

9
10 **Data sharing statement**
11

12 The datasets used in this study are not publicly available, but these can be provided on
13
14 reasonable request after the approval.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Reference

1. Wang Y-J, Li Z-X, Gu H-Q, Zhai Y, Jiang Y, Zhao X-Q, Wang Y-L, Yang X, Wang C-J, Meng X, et al. China Stroke Statistics 2019: A Report from the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, the Chinese Stroke Association, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations. *Stroke Vasc. Neurol.* 2020;5:211–239.
2. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KMA, et al. High-dose Atorvastatin after Stroke or Transient Ischemic Attack. *N. Engl. J. Med.* 2006;355:549–559.
3. Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Béjot Y, Cabrejo L, Cha J-K, Ducrocq G, Giroud M, et al. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. *N. Engl. J. Med.* 2020;382:9.
4. Klijn CJ, Paciaroni M, Berge E, Korompoki E, Kõrv J, Lal A, Putaala J, Werring DJ. Antithrombotic Treatment for Secondary Prevention of Stroke and Other Thromboembolic Events in Patients with Stroke or Transient Ischemic Attack and Non-valvular Atrial Fibrillation: A European Stroke Organisation guideline. *Eur. stroke J.* 2019;4:198–223.

- 1
2
3
4 5. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockcroft KM, Gutierrez J,
5
6 Lombardi-Hill D, Kamel H, Kernan WN, Kittner SJ, Leira EC, et al. 2021
7
8
9 Guideline for the Prevention of Stroke in Patients with Stroke and Transient
10
11
12 Ischemic Attack: A Guideline from the American Heart Association/American
13
14 Stroke Association. *Stroke*. 2021;52:e364–e467.
15
16
- 17 6. Amarenco P, Kim JS, Labreuche J, Giroud M, Lee BC, Mahagne MH,
18
19 Nighoghossian N, Simon T, Steg PG, Touboul PJ, et al. Treat Stroke to Target
20
21
22 Trial Design: First Trial Comparing Two LDL Targets in Patients with
23
24
25 Atherothrombotic Strokes. *Eur. Stroke J*. 2019;4:271–280.
26
27
- 28 7. Qureshi AI, Caplan LR. Intracranial Atherosclerosis. *Lancet (London,*
29
30
31
32
33 *England)*. 2014;383:984–998.
34
- 35 8. Wong LKS. Global Burden of Intracranial Atherosclerosis. *Int. J. stroke Off. J.*
36
37
38
39 *Int. Stroke Soc*. 2006;1:158–159.
40
- 41 9. Mok V, Srikanth V, Xiong Y, Phan TG, Moran C, Chu S, Zhao Q, Chu WWC,
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
60 Wong A, Hong Z, et al. Race-ethnicity and Cerebral Small Vessel Disease--
Comparison between Chinese and White Populations. *Int. J. stroke Off. J. Int.*
Stroke Soc. 2014;9 Suppl A1:36–42.
10. Wolma J, Nederkoorn PJ, Goossens A, Vergouwen MDI, van Schaik IN,
Vermeulen M. Ethnicity a Risk factor? The Relation between Ethnicity and
Large- and Small-vessel Disease in White People, Black People, and Asians
within a Hospital-based Population. *Eur. J. Neurol*. 2009;16:522–527.


- 1
2
3
4 11. Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of Cholesterol-
5
6 lowering with Simvastatin on Stroke and Other Major Vascular Events in
7
8 20536 people with cerebrovascular disease or other high-risk conditions.
9
10 *Lancet (London, England)*. 2004;363:757–767.
11
12
- 13
14
15 12. Oyama K, Giugliano RP, Blazing MA, Park J-G, Tershakovec AM, Sabatine
16
17 MS, Cannon CP, Braunwald E. Baseline Low-Density Lipoprotein Cholesterol
18
19 and Clinical Outcomes of Combining Ezetimibe with Statin Therapy in
20
21 IMPROVE-IT. *J. Am. Coll. Cardiol.* 2021;78:1499–1507.
22
23
- 24
25
26 13. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy
27
28 SA, Kuder JF, Wang H, Liu T, Wasserman SM, et al. Evolocumab and Clinical
29
30 Outcomes in Patients with Cardiovascular Disease. *N. Engl. J. Med.*
31
32 2017;376:1713–1722.
33
34
- 35
36
37 14. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand A-C, Stein EA.
38
39 Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase
40
41 Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients
42
43 with Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin
44
45 Therapy. *J. Am. Coll. Cardiol.* 2012;59:2344–2353.
46
47
- 48
49
50 15. Wang Y, Jing J, Meng X, Pan Y, Wang Y, Zhao X, Lin J, Li W, Jiang Y, Li Z,
51
52 et al. The Third China National Stroke Registry (CNSR-III) for Patients with
53
54 Acute Ischaemic Stroke or Transient Ischaemic Attack: Design, Rationale and
55
56 Baseline Patient Characteristics. *Stroke Vasc. Neurol.* 2019;4:158–164.
57
58
59
60

- 1
2
3
4 16. Soran H, Adam S, Durrington PN. Optimising Treatment of Hyperlipidaemia:
5
6 Quantitative Evaluation of UK, USA and European Guidelines Taking Account
7
8 of Both LDL Cholesterol Levels and Cardiovascular Disease Risk.
9
10
11 *Atherosclerosis*. 2018;278:135–142.
12
13
14
15 17. (EAS) TTF for the management of dyslipidaemias of the ESC of C (ESC) and
16
17 EAS. 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid
18
19 Modification to Reduce Cardiovascular Risk. *Atherosclerosis*. 2019;290:140–
20
21 205.
22
23
24
25
26 18. Zhang X, Liu J, Wang M, Qi Y, Sun J, Liu J, Wang Y, Hao Y, Li Y, Zhou M,
27
28 et al. Twenty-year Epidemiologic Study on LDL-C Levels in Relation to the
29
30 Risks of Atherosclerotic Event, Hemorrhagic Stroke, and Cancer Death among
31
32 Young and Middle-aged Population in China. *J. Clin. Lipidol*. 2018;12:1179-
33
34 1189.e4.
35
36
37
38
39 19. Giugliano RP, Pedersen TR, Saver JL, Sever PS, Keech AC, Bohula EA,
40
41 Murphy SA, Wasserman SM, Honarpour N, Wang H, et al. Stroke Prevention
42
43 with the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor
44
45 Evolocumab Added to Statin in High-Risk Patients With Stable
46
47 Atherosclerosis. *Stroke*. 2020;51:1546–1554.
48
49
50
51
52
53 20. Wang X, Dong Y, Qi X, Huang C, Hou L. Cholesterol Levels and Risk of
54
55 Hemorrhagic Stroke: a Systematic Review and Meta-analysis. *Stroke*.
56
57 2013;44:1833–1839.
58
59
60

- 1
2
3
4 21. Wang C-J, Wang Y-L, Li Z-X, Wang Y-J. The Management of LDL
5
6 Cholesterol and Predictors of Goal Achievement in Stroke Patients in China: A
7
8 Cross-Sectional Study. *CNS Neurosci. Ther.* 2016;22:577–583.
9
10
11
12 22. Tomlinson B, Chan P, Liu Z-M. Statin Responses in Chinese Patients. *J.*
13
14 *Atheroscler. Thromb.* 2018;25:199–202.
15
16
17
18 23. Tomlinson B, Chan P, Liu Z-M. Statin Intolerance-An Asian Perspective. *J.*
19
20 *Atheroscler. Thromb.* 2020;27:485–488.
21
22
23
24 24. Sanz-Cuesta BE, Saver JL. Lipid-Lowering Therapy and Hemorrhagic Stroke
25
26 Risk: Comparative Meta-Analysis of Statins and PCSK9 Inhibitors. *Stroke.*
27
28 2021;52:3142–3150.
29
30
31
32 25. Coull AJ, Lovett JK, Rothwell PM. Population Based Study of Early Risk of
33
34 Stroke after Transient Ischaemic Attack or Minor Stroke: Implications for
35
36 Public Education and Organisation of Services. *BMJ.* 2004;328:326.
37
38
39
40 26. Pan Y, Li Z, Li J, Jin A, Lin J, Jing J, Li H, Meng X, Wang Y, Wang Y.
41
42 Residual Risk and Its Risk Factors for Ischemic Stroke with Adherence to
43
44 Guideline-Based Secondary Stroke Prevention. *J. stroke.* 2021;23:51–60.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Dose-response-relationship curves

Adjusted odds ratio of events and MACE at 3 months and 12 months according to LDL-C at baseline in patients. (a) stroke at 3 months; (b) ischemic stroke at 3 months; (c) hemorrhagic stroke at 3 months; (d) MACE at 3 months; (e) stroke at 12 months; (f) ischemic stroke at 12 months; (g) hemorrhagic stroke at 12 months; (h) MACE at 12 months. The full line indicates the adjusted hazard ratio and the dashed lines the 95% confidence interval bands. Reference is LDL-C >2.6mmol/L. Data were fitted using a logistic regression model of restricted cubic spline with three knots (the 5th, 50th, 90th percentiles) for LDL-C level, adjusting for potential covariates.



Dose-response-relationship curves

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	1 3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	7 N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8
Bias	9	Describe any efforts to address potential sources of bias	9
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	10 10 10 11 N/A
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	11 N/A N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	11 N/A 12
Outcome data	15*	Report numbers of outcome events or summary measures over time	13

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	13
2			(b) Report category boundaries when continuous variables were categorized	13
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	14
4				
5	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	14
6				
7				
8				
9				
10				
11	Discussion			
12	Key results	18	Summarise key results with reference to study objectives	17
13	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	20
14				
15	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	18
16				
17	Generalisability	21	Discuss the generalisability (external validity) of the study results	18
18				
19				
20				
21	Other information			
22	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	21
23				
24				

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

Lipid Management in Ischemic Stroke or Transient Ischemic Attack in China: Result from China National Stroke Registry III

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-069465.R2
Article Type:	Original research
Date Submitted by the Author:	16-Jan-2023
Complete List of Authors:	Xu, Yuyuan; Beijing Tiantan Hospital, Chen, Weiqi; Beijing Tiantan Hospital Wang, Mengxing; Beijing Tiantan Hospital PAN, YUESONG; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases Li, Zixiao; Beijing Tiantan Hospital, Neurology Liu, Liping; Beijing Tiantan Hospital, Neurology; China National Clinical Research Center for Neurological Diseases, Zhao, Xingquan; Beijing Tiantan Hospital, Neurology Wang, Yilong; Beijing Tiantan Hospital, Department of Neurology Li, Hao; Beijing Tiantan Hospital Wang, Yongjun; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases Meng, Xia; Beijing Tiantan Hospital, Department of Neurology; Capital Medical University
Primary Subject Heading:	Medical management
Secondary Subject Heading:	Neurology, Medical management
Keywords:	Neurology < INTERNAL MEDICINE, Lipid disorders < DIABETES & ENDOCRINOLOGY, Stroke medicine < INTERNAL MEDICINE, Stroke < NEUROLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Lipid Management in Ischemic Stroke or Transient Ischemic Attack in China:**
5
6
7 **Result from China National Stroke Registry III**
8
9

10
11 Yu-Yuan Xu, MD^{a, b}; Wei-Qi Chen, MD^{a, b}; Meng-Xing Wang, PhD^b; Yue-Song
12
13 Pan, PhD^b; Zi-Xiao Li, MD^{a, b}; Li-Ping Liu, MD^{a, b}; Xing-Quan Zhao, MD^{a, b}; Yi-
14
15 Long Wang, MD^{a, b}; Hao Li, PhD^b; Yong-Jun Wang, MD^{a, b, c, d}; Xia Meng, MD^{a, b};
16
17
18 on behalf of the CNSR-III Investigators
19
20
21

22
23
24
25 ^a Department of Neurology, Beijing Tiantan Hospital, Capital Medical University,
26
27 Beijing, China
28

29
30 ^b China National Clinical Research Center for Neurological Diseases, Beijing Tiantan
31
32 Hospital, Capital Medical University, Beijing, China
33

34
35 ^c Advanced Innovation Center for Human Brain Protection, Capital Medical
36
37 University, Beijing, China
38

39
40 ^d Research Unit of Artificial Intelligence in Cerebrovascular Disease, Chinese
41
42 Academy of Medical Sciences, 2019RU018
43
44

45
46
47
48 **Running title:** Lipid management in Ischemic Stroke or TIA
49

50
51 Correspondence to Dr. Xia Meng: No. 119 South 4th Ring West Road, Fengtai
52
53 District, Beijing 100070, China. Email: mengxia45@163.com. Phone: +86 10
54
55 59978245. Fax: +86 10 59973383.
56

57
58 Number of Tables: 7
59
60

1
2
3
4 Number of Figures: 1
5

6
7 Word count: 3551
8
9

10 **Keywords:** low-density lipoprotein cholesterol, lipid-lowering treatment, ischemic
11
12 stroke, second prevention
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Abstract

Background and purpose: Dyslipidaemia is a significant risk factor for ischemic stroke and transient ischemic attack (TIA). The aims of the study were to assess the management of low-density lipoprotein cholesterol (LDL-C) and the goal achievement, as well as to investigate the association between baseline LDL-C level, lipid-lowering treatment (LLT), and stroke recurrence in patients with ischemic stroke or TIA.

Methods: We derived data from the Third China National Stroke Registry (CNSR-III). The primary outcome was a new stroke, LDL-C goal (LDL-C<1.8mmol/L and LDL-C<1.4mmol/L, respectively) achievement rates, and LLT compliance within 3, 6, and 12 months. The associations among the baseline LDL-C level, LLT at discharge, and outcomes were also assessed.

Results: Among the 15,166 patients, over 90% of patients received LLT during hospitalization and 2 weeks after discharge; the LLT compliance was 84.5% at 3 months, 75.6% at 6 months, and 64.8% at 12 months. At 12 months, LDL-C goal achievement rate for 1.8mmol/L and 1.4mmol/L was 35.4% and 17.6%, respectively. LLT at discharge was associated with reduced risk of ischemic stroke recurrence (HR=0.687, 95% CI: 0.480-0.985, p=0.0411) at 3 months. The rate of LDL-C reduction from baseline to 3-month follow-up was not associated with a reduced risk of stroke recurrence or major adverse cardiovascular events (MACE) at 12 months. Patients with baseline LDL-C \leq 1.4mmol/L had a numerically lower risk of stroke, ischemic stroke and MACE at both 3 months and 12 months.

1
2
3
4 **Conclusions:** The LDL-C goal achievement rate has increased mildly in the stroke
5
6 and TIA population in mainland China. Lowered baseline LDL-C level was
7
8 significantly associated with a decreased short- and long-term risk of ischemic stroke
9
10 among stroke and TIA patients. LDL-C<1.4mmol/L might be a safe standard for this
11
12 population.
13
14
15
16
17
18
19

20 **Strengths and limitations of this study**

- 21
22 1. This hospital-based study analyzed the low-density lipoprotein cholesterol (LDL-C)
23
24 levels and lipid-lowering therapy (LLT) in patients with ischemic stroke (IS)/transient
25
26 ischemic attack (TIA) in the general population of mainland China.
27
28
- 29
30 2. The study included the largest sample of IS/TIA patients and recorded detailed
31
32 prognostic characteristics.
33
34
- 35
36 3. The design of the cohort study did not allow for further detailed analysis of lipid-
37
38 lowering medication use, such as dose change and duration.
39
40
- 41
42 4. Some undetected confounding factors, including residual risk, were not able to be
43
44 assessed in this study.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Low-density lipoprotein cholesterol (LDL-C) has been well established as an independent risk factor for ischemic stroke ¹. Intensive lipid-lowering treatment (LLT) has been proven to reduce cardiovascular event recurrence in ischemic stroke (IS)/transient ischemic attack (TIA) patients. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study ² showed that intensive atorvastatin treatment for five years reduced the risk of stroke recurrence up to 16% (HR 0.84, 95% CI 0.71-0.99; P < 0.03) in IS/TIA. Recently, Treat Stroke to Target (TST) study ³ also demonstrated that IS/TIA patients who had a target LDL-C level of less than 70 mg/dl (1.8mmol/L) had a lower risk of subsequent cardiovascular events than those who had a target range of 90 to 110 mg/dl (HR 0.78, 95% CI 0.61-0.98; P=0.04). Therefore, European Stroke Organisation (ESO) and American Stroke Association (ASA) both updated the IS/TIA second prevention guideline with a recommendation of LDL-C target goal to be less than 70mg/dl (1.8mmol/L) ^{4,5}.

However, there are still clinical questions not thoroughly investigated. Firstly, SPARCL and TST trials are randomized controlled trials conducted mainly in the Caucasian population ^{2,6}, whereas studies focusing on the Asian population on lipid management in stroke patients are limited. Since there are more intracranial artery stenosis (ICAS) ^{7,8} and cerebral small vessel disease (CSVD) patients in Asia ^{9,10}, especially in east Asia, the applicability of the conclusions of these two trials to Asian people should be discreet. Secondly, there are inconsistencies and conflicts about whether the reduced LDL-C level, especially during the acute or subacute phase,

1
2
3
4 could increase the risk of intracranial hemorrhage (ICH). In the SPARCL study,
5
6 subgroup analysis indicated that atorvastatin treatment might increase the risk of ICH,
7
8
9 which led to a big concern for statin usage during the acute phase of IS/TIA ¹¹. In
10
11 contrast, the TST study showed that the incidence of ICH did not differ significantly
12
13 between the lower- and higher-target groups ³. Thirdly, with emerging evidence from
14
15 non-statin therapies such as IMPROVE-IT ¹², FOURIER ¹³, and ODYSSEY ¹⁴, a lower
16
17 LDL-C target of less than 1.4mmol/L or even 1.0mmol/L has been recommended for
18
19 adoption as international guidelines. However, the benefits of a lower LDL-C target
20
21 lower than 1.8mmol/L have not been investigated.
22
23
24
25

26
27 The Third China National Stroke Registry (CNSR-III) is one of the world's most
28
29 extensive IS/TIA cohort studies and it includes comprehensive medical histories,
30
31 centralized the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification
32
33 judication, and follow-up outcomes. We aimed to collect data from CNSR-III to
34
35 investigate the China's current lipid management practices and the associations
36
37 between LDL-C level, LLT, and stroke recurrence in ischemic stroke or TIA patients.
38
39
40
41

42 **Methods**

43 **Study design and participants**

44
45
46
47 This study was based on the CNSR-III database. The CNSR-III is a nationwide
48
49 clinical registry of ischemic stroke or transient ischemic attack (TIA) based on
50
51 etiology, imaging, and biological markers in China from August 2015 to March 2018
52
53
54
55
56
57
58
59
60
15. 201 participating hospitals were selected in China, and 15,166 patients were

1
2
3
4 eligible and had complete information at baseline. The total 15,166 patients were
5
6 included in the analysis. Among all the clinical centers included in CNSR-III, 169
7
8 centers voluntarily participated in the prespecified blood biomarker substudy, with all
9
10 the patients at these centers participating in the biomarker substudy. Such patients
11
12 provided a separate written informed consent form that included their consent for
13
14 blood sample collection and further study of biomarkers. The study protocol of the
15
16 CNSR-III was approved by the ethics committee at Beijing Tiantan Hospital (IRB
17
18 approval number: KY2015-001-01) and all participating centres. Every participant
19
20 provided written informed consent before participation.
21
22

23
24 To eligible for this second analysis research, patients had to meet the following
25
26 criteria: (1) age 18 or older; (2) hospitalized with a primary diagnosis of acute
27
28 ischemic stroke or transient ischemic attack; (3) direct hospital admission from a
29
30 physician's clinic or an emergency department; and (4) informed consent provided by
31
32 the patient or legally authorized representative. Patients with intracranial hemorrhage,
33
34 subarachnoid hemorrhage, or undetermined stroke were not included in this study.
35
36

37
38 This study was approved by ethics committee at Beijing Tiantan Hospital (KY2019-
39
40 109-01).
41
42

43 44 45 46 47 48 49 **Data Collection and Management**

50
51
52 Patient information, including demographics, risk factors, comorbidities, medications,
53
54 selected laboratory tests, and hospital-level characteristics, were collected
55
56 systematically during hospitalization and at discharge by trained research coordinators
57
58
59
60

1
2
3
4 at each participating hospital. National Institutes of Health Stroke Scale (NIHSS)
5
6 score at admission, and ischemic stroke recurrence, composite vascular event, and
7
8 modified Rankin Scale (mRS) at 3 months and 1 year after stroke onset were also
9
10 collected.
11
12

13
14 Venous blood samples were collected from fasting patients within 24 hours from
15
16 admission. Serum specimens were extracted, aliquoted, and transported through the
17
18 cold chain to the central laboratory in Beijing Tiantan Hospital and stored at -80°C.
19
20 LDL-C measurements were centrally and blindly assayed by enzymatic method on the
21
22 Cobas 8000 analyzer c702 module (Roche Diagnostics, Mannheim, Germany).
23
24
25
26
27

28 **Follow-Up and Clinical Outcome Evaluations**

29
30

31
32 Patients were followed up through face-to-face interviews at 3 months and by
33
34 telephone interviews at 6 and 12 months by trained research coordinators who
35
36 followed a standardized interview protocol. Information collected at each follow-up
37
38 included cardio- and cerebrovascular events, all causes of death, and medications use.
39
40 Vascular events were confirmed with the treating hospital, and death was either
41
42 confirmed based on a death certificate issued by the attended hospital or the local civil
43
44 registry.
45
46
47
48
49

50 The primary outcome was a new stroke (defined as a new neurological deficit lasting
51
52 more than 24 hours or re-hospitalization with a diagnosis of ischemic stroke,
53
54 intracerebral hemorrhage, or subarachnoid hemorrhage), LDL-C goal (LDL-
55
56 C<1.4mmol/L, and LDL-C<1.8mmol/L, respectively) achievement rates and LLT
57
58
59
60

1
2
3
4 compliance in China within 3, 6, and 12 months. The secondary outcomes included
5
6 major adverse cardiovascular events (including stroke, myocardial infarction, or
7
8 vascular death) and all caused death at 3 months and 12 months.
9

10
11 All reported efficacy and safety outcomes were verified by a central independent
12
13 adjudication committee blinded to study treatment assignments and baseline LDL-C
14
15 level.
16
17

18
19 Patients were categorized into four groups according to the baseline LDL-C levels and
20
21 lipid-lowering treatment during hospitalization and after discharge: LDL-
22
23 $C \leq 1.4 \text{ mmol/L}$, $1.4 \text{ mmol/L} < \text{LDL-C} \leq 1.8 \text{ mmol/L}$, $1.8 \text{ mmol/L} < \text{LDL} \leq 2.6 \text{ mmol/L}$,
24
25 $\text{LDL} > 2.6 \text{ mmol/L}$.
26
27

28
29 LLT compliance was defined as the continuation of LLT medication from discharge
30
31 to 3, 6, or 12 months after the onset of symptoms. Patients assigned to LLT at
32
33 discharge but later discontinuing LLT at any follow-up point within 3, 6, or 12
34
35 months were considered “non-persistent”. Patients were considered persistent if they
36
37 discontinued one medication but replaced it with another statin medication that they
38
39 continued taking through 3, 6, or 12 months after enrollment.
40
41
42
43
44
45

46 **Statistical analysis**

47
48
49 Baseline variables were presented as median with interquartile range (IQR) for
50
51 continuous variables and percentages for categorical variables.
52
53

54
55 To analyze the association of baseline LDL-C levels and outcomes, we only included
56
57 those subjects who provided 3-month or 12-month bio-sample. Univariate and
58
59
60

1
2
3
4 multivariate Cox proportional hazard regression models were used. The model
5
6 included the following covariates: age, sex, education, current smoking, heavy
7
8 drinking, medical history, stroke severity on the NIHSS, history of stroke, history of
9
10 diabetes, and history of hypertension. Adjusted hazard ratios (HRs) with 95%
11
12 confidence intervals (CIs) were calculated. The dose-response-relationship curves
13
14 were also presented.
15
16
17

18
19 To analyze the effect of discharge LLT on outcomes, we excluded subjects who
20
21 reached the end point (stroke recurrence or MACE, death, and loss to follow-up)
22
23 during hospitalization. We performed a univariate model and multivariate analysis by
24
25 adjusting for age, sex, education, current smoking, heavy drinking, medical history,
26
27 stroke severity on the NIHSS, history of stroke, history of diabetes, and history of
28
29 hypertension.
30
31
32
33

34
35 In addition, to analyze the association of 3-month LDL-C change with stroke
36
37 recurrence and MACE within 12 months, we excluded subjects who reached the end
38
39 point (stroke recurrence or MACE, death, and loss to follow-up) within 3 months.
40
41
42

43 All statistical analyses in the study were performed by SAS 9.4 software. All
44
45 statistical analysis adopted a two-sided test which was performed at a 5% significance
46
47 level.
48
49
50

51 **Patient and Public Involvement**

52
53
54
55
56
57
58
59
60

This registry study was designed and conducted without patient and public involvement. Our results will be disseminated to the public through publication in this journal.

Results

Characteristics of study participants

From August 2015 to March 2018, a total of 15166 patients with acute stroke and TIA were recruited to the CNSR-III and entered our final analysis. The average age of patients was 62.2 ± 11.3 years, 31.7% of patients were women, 14,146 (93.3%) had an index event of stroke, and 1020 (6.7%) had a TIA¹⁵.

Baseline LDL-C levels

There were 10,738 patients in LDL-C analysis set: 1,407 (13.1%), 1,636 (15.2%), 3,655 (34.0%), and 4,040 (37.6%) patients with the baseline LDL-C ≤ 1.4 mmol/L, 1.4–1.8 mmol/L, 1.8–2.6 mmol/L, ≥ 2.6 mmol/L, respectively (Table 1).

Table 1. Baseline Characteristics for the LDL-C analysis set

Variables	LDL \leq 1.4mmol/L N=1407	1.4 < LDL \leq 1.8mmol/L N=1636	1.8 < LDL \leq 2.6mmol/L N=3655	LDL $>$ 2.6mmol/L N=4040	P Value*
Women, n (%)	378 (26.9)	439 (26.8)	1057 (28.9)	1517 (37.6)	<0.001
Mean age, years (SD)	60.8 \pm 11.9	62.4 \pm 11.3	62.2 \pm 11.3	62.8 \pm 11.1	<0.001
Ethnicity (non-Han), n (%)	30 (2.1)	49 (3.0)	122 (3.3)	104 (2.6)	0.07
Current smoker, n (%)	435 (30.9)	525 (32.1)	1239 (33.9)	1198 (29.7)	<0.001
Heavy drinker, n (%)*	185 (13.2)	210 (12.8)	545 (14.9)	589 (14.6)	0.12
Triglycerides (IQR)	1.3 (0.9-1.9)	1.3 (1.0-1.8)	1.3 (1.0-1.8)	1.5 (1.1-2.0)	<0.001
TC, mmol/L	2.7 (2.4-3.1)	3.2 (3.0-3.5)	3.8 (3.5-4.1)	4.9 (4.5-5.5)	<0.001
HDL-C, mmol/L	0.8 (0.7-1.0)	0.9 (0.8-1.1)	0.9 (0.8-1.1)	1.0 (0.8-1.2)	<0.001
LDL-C, mmol/L	1.2 (1.0-1.3)	1.6 (1.5-1.7)	2.2 (2.0-2.4)	3.2 (2.9-3.8)	<0.001
BMI	24.4 (22.5-26.4)	24.5 (22.7-26.6)	24.4 (22.5-26.4)	24.5 (22.7-26.7)	0.06
Systolic pressure, mmHg	145.0 (132.5-160.0)	146.5 (133.0-161.0)	148.5 (135.0-163.5)	150.0 (136.0-166.5)	<0.001
Medical history, n (%)					
Ischemic stroke	369 (26.2)	429 (26.2)	715 (19.6)	748 (18.5)	<0.001

1						
2						
3	TIA	44 (3.1)	46 (2.8)	115 (3.6)	102 (2.5)	0.38
4	Coronary heart diseases	147 (10.5)	193 (11.8)	366 (10.0)	449 (11.1)	0.20
5	Atrial fibrillation	93 (6.6)	124 (7.6)	272 (7.4)	257 (6.4)	0.19
6	Hypertension	897 (63.8)	1045 (63.9)	2295 (62.8)	2516 (62.3)	0.62
7	Diabetes mellitus	386 (27.4)	394 (24.1)	824 (22.5)	960 (23.8)	0.004
8	Hypercholesterolemia	119 (8.5)	120 (7.3)	302 (8.3)	341 (8.4)	0.56
9	NIHSS at admission,					
10	median (IQR)	3.0 (1.0-6.0)	3.0 (1.0-6.0)	3.0 (1.0-6.0)	3.0 (1.0-6.0)	<0.001
11	NIHSS 0–3	743 (52.8)	914 (55.9)	1974 (54.0)	2073 (51.3)	0.009
12	NIHSS≥4	664 (47.2)	722 (44.1)	1681 (46.0)	1967 (48.7)	
13	mRS (IQR)	0 (0-1.0)	0 (0-1.0)	0 (0-1.0)	0 (0-0)	<0.001
14	Stroke subtype, n (%)					
15	LAA	303 (21.5)	390 (23.8)	933 (25.5)	1092 (27.0)	0.0095
16	CE	81 (5.8)	96 (5.9)	251 (6.9)	256 (6.3)	
17	SAO	312 (22.2)	359 (21.9)	740 (20.3)	819 (20.3)	
18	Other	21 (1.5)	16 (1.0)	38 (1.0)	47 (1.2)	
19	Unknown	690 (49.0)	775 (47.4)	1693 (46.3)	1826 (45.2)	
20	Prestroke antiplatelet					
21	therapy, n (%)	1357 (97.4)	1569 (97.1)	3504 (96.7)	3894 (97.0)	0.57
22	Prestroke LLT, n (%)	1359 (97.6)	1558 (96.4)	3498 (96.5)	3897 (97.1)	0.15
23	Statin, n (%)	1355 (97.3)	1556 (96.3)	3491 (96.3)	3887 (96.9)	0.27

TC: total cholesterol. HDL-C: high-density lipoprotein cholesterol. LDL-C: low-density lipoprotein cholesterol. BMI: body mass index. TIA: transient ischemic attack. NIHSS: National Institutes of Health Stroke Scale. mRS: modified Rankin Scale. LAA: large artery atherosclerosis. CE: cardiogenic embolism. SAO: small artery occlusion. LLT: lipid-lowering therapy.

Patients in the lower baseline LDL-C level group (≤ 1.4 mmol/L) were more likely to be younger ($p < 0.0001$) and had a greater prevalence of cardiovascular risk factors (previous stroke, hypertension, hypercholesterolemia, diabetes mellitus, and history of stroke) ($p < 0.0001$) and lower levels of triglycerides, total cholesterol and high-density lipoprotein (HDL) ($p < 0.0001$). About 97% of the patients had a history of antiplatelet and lipid-lowering therapy, and the rates showed no difference among the four baseline LDL-C groups.

Association between baseline LDL-C levels and outcomes at 3 months and 12 months

There were 656 (6.11%) new stroke occurrences at 3 months and 1037 (9.66%) at 12 months (**Table 2**).

Table 2. Association between baseline LDL-C levels and outcomes at 3 months and 12 months

	Total	Events (n%)	HR (95% CI) Unadjusted	<i>P</i> value	HR (95% CI) Adjusted	<i>P</i> value
3 months						
Stroke recurrence						
LDL≤1.4mmol/L	1407	69 (4.9)	0.72 (0.55-0.94)	0.01	0.74 (0.57-0.97)	0.03
1.4<LDL≤1.8mmol/L	1636	95 (5.8)	0.85 (0.68-1.08)	0.18	0.89 (0.70-1.12)	0.32
1.8<LDL≤2.6mmol/L	3655	219 (6.0)	0.88 (0.74-1.05)	0.17	0.91 (0.76-1.08)	0.28
LDL>2.6mmol/L	4040	273 (6.8)	Reference	-	Reference	-
Ischemic stroke						
LDL≤1.4mmol/L	1407	65 (4.6)	0.72 (0.55-0.95)	0.02	0.74 (0.56-0.98)	0.03
1.4<LDL≤1.8mmol/L	1636	88 (5.4)	0.84 (0.66-1.07)	0.16	0.87 (0.68-1.11)	0.27
1.8<LDL≤2.6mmol/L	3655	201 (5.5)	0.86 (0.72-1.04)	0.11	0.89 (0.74-1.07)	0.22
LDL>2.6mmol/L	4040	257 (6.4)	Reference	-	Reference	-
Hemorrhagic stroke						
LDL≤1.4mmol/L	1407	4 (0.3)	0.52 (0.18-1.51)	0.23	0.55 (0.19-1.61)	0.28
1.4<LDL≤1.8mmol/L	1636	9 (0.6)	1.01 (0.46-2.19)	0.98	1.03 (0.47-2.26)	0.93
1.8<LDL≤2.6mmol/L	3655	20 (0.6)	1.00 (0.55-1.84)	0.99	0.93 (0.50-1.73)	0.82
LDL>2.6mmol/L	4040	22 (0.5)	Reference	-	Reference	-
MACE						
LDL≤1.4mmol/L	1407	71 (5.1)	0.72 (0.56-0.94)	0.01	0.75 (0.57-0.97)	0.03
1.4<LDL≤1.8mmol/L	1636	100 (6.1)	0.88 (0.70-1.10)	0.27	0.91 (0.72-1.15)	0.42
1.8<LDL≤2.6mmol/L	3655	231 (6.3)	0.91 (0.77-1.08)	0.29	0.93 (0.78-1.11)	0.43
LDL>2.6mmol/L	4040	279 (6.9)	Reference	-	Reference	-
12 months						
Stroke recurrence						
LDL≤1.4mmol/L	1407	114 (8.1)	0.76 (0.62-0.93)	0.009	0.77 (0.62-0.95)	0.01
1.4<LDL≤1.8mmol/L	1636	158 (9.7)	0.91 (0.76-1.08)	0.30	0.92 (0.76-1.10)	0.36
1.8<LDL≤2.6mmol/L	3655	339 (9.7)	0.87 (0.76-1.01)	0.06	0.89 (0.77-1.03)	0.12
LDL>2.6mmol/L	4040	426 (10.5)	Reference	-	Reference	-
Ischemic stroke						
LDL≤1.4mmol/L	1407	102 (7.6)	0.72 (0.58-0.90)	0.004	0.73 (0.59-0.91)	0.005
1.4<LDL≤1.8mmol/L	1636	145 (8.9)	0.89 (0.73-1.07)	0.22	0.90 (0.74-1.09)	0.27
1.8<LDL≤2.6mmol/L	3655	304 (8.3)	0.83 (0.72-0.97)	0.02	0.86 (0.74-1.00)	0.04
LDL>2.6mmol/L	4040	400 (9.9)	Reference	-	Reference	-
Hemorrhagic stroke						
LDL≤1.4mmol/L	1407	12 (0.9)	0.96 (0.50-1.84)	0.89	0.97 (0.50-1.88)	0.93
1.4<LDL≤1.8mmol/L	1636	15 (0.9)	1.03 (0.56-1.87)	0.94	1.02 (0.56-1.88)	0.95
1.8<LDL≤2.6mmol/L	3655	37 (1.0)	1.13 (0.72-1.80)	0.59	1.10 (0.69-1.75)	0.69
LDL>2.6mmol/L	4040	36 (0.9)	Reference	-	Reference	-
MACE						
LDL≤1.4mmol/L	1407	119 (8.5)	0.76 (0.62-0.93)	0.008	0.77 (0.62-0.94)	0.01
1.4<LDL≤1.8mmol/L	1636	170 (10.4)	0.94 (0.79-1.12)	0.47	0.94 (0.79-1.13)	0.50
1.8<LDL≤2.6mmol/L	3655	363 (9.9)	0.90 (0.78-1.03)	0.13	0.91 (0.79-1.05)	0.20
LDL>2.6mmol/L	4040	444 (11.0)	Reference	-	Reference	-

LDL-C: low-density lipoprotein cholesterol. MACE: major adverse cardiovascular events.

1
2
3
4 Compared with patients with other LDL-C level subgroups, the patients with LDL-C
5
6 ≤ 1.4 mmol/L had a numerically lower risk of stroke (HR=0.742, 95% CI: 0.568-0.970,
7
8 p=0.0291), ischaemic stroke (HR=0.741, 95% CI: 0.562-0.976, p=0.0329) and MACE
9
10 (HR=0.746, 95% CI: 0.573-0.972, p=0.0297) at 3 months. Similar results were found
11
12 for the outcome of stroke (HR=0.767, 95% CI: 0.622-0.946, p=0.0131), ischaemic
13
14 stroke (HR=0.731, 95% CI: 0.587-0.911, p=0.0052) and MACE (HR=0.766, 95% CI:
15
16 0.624-0.940, p=0.0106) at 12 months after the initial event. Lower baseline LDL-C
17
18 level was not associated with an increased risk of hemorrhagic stroke at either 3
19
20 months or 12 months (**Table 2**). Using a Cox regression model with restricted cubic
21
22 splines, a strong association was also found between baseline LDL-C level and risk of
23
24 stroke, ischemic stroke, hemorrhagic stroke, and MACE (**Figure 1**).

25 26 27 28 29 30 31 32 **Lipid-lowering management, LLT compliance, and association of discharge LLT** 33 34 35 **and outcomes**

36
37 LLT management and compliance of the included patients during hospitalization, at
38
39 discharge, 3 months, 6 months, and 12 months after the initial event were shown in

40 41 42 43 **Table 3.**

44
45
46 **Table 3. Lipid-lowering Treatment (LLT) and the compliance of patients in**

47 48 **CNSR-III**

	Hospitalization	Discharge	3 months	6 months	12 months
Non LLT	547 (3.6)	1300 (8.6)	2590 (17.4)	3007 (22.4)	3754 (26.0)
LLT	14506 (96.4)	13831 (91.4)	12271 (82.6)	11726 (77.6)	10682 (74.0)
Compliance					
Non-Persistent	/	/	2147 (15.5)	3382 (24.5)	4863 (35.2)
Persistent	/	/	11684 (84.5)	10449 (75.6)	8968 (64.8)

Over 90% of patients received LLT during hospitalization and for 2 weeks after discharge. The LLT compliance was 84.5% at 3 months, 75.6% at 6 months, and 64.8% at 12 months. The drug regimens of LLT for the patients in CNSR-III at 3 months, 6 months, and 12 months were shown in **Table 4**.

Table 4. Lipid-lowering Treatment of the included patients in CNSR-III at 3-month, 6-month, 12-month follow-up (n=15166)

Treatment	Patients with statins, N (%)				
	Hospitalization	Discharge	3 months	6 months	12 months
Atorvastatin	10527 (69.41)	9851 (64.95)	8656 (57.08)	8228 (54.25)	7470 (49.25)
<40mg	7442 (70.71)	8770 (89.03)	8284 (95.7)	7963 (96.78)	7269 (97.35)
≥40mg	3083 (29.29)	1081 (10.97)	372 (4.3)	265 (3.22)	198 (2.65)
Rosuvastatin	3546 (23.38)	3395 (22.39)	2903 (19.14)	2779 (18.32)	2489 (16.41)
<20mg	2876 (81.15)	2983 (87.86)	2650 (91.38)	2536 (91.29)	2313 (92.93)
≥20mg	668 (18.85)	412 (12.14)	250 (8.62)	242 (8.71)	176 (7.07)
Simvastatin	272 (1.79)	239 (1.58)	390 (2.57)	411 (2.71)	444 (2.93)
Pravastatin	166 (1.09)	165 (1.09)	137 (0.9)	128 (0.84)	100 (0.66)
lovastatin	25 (0.16)	24 (0.16)	33 (0.22)	33 (0.22)	30 (0.2)
Fluvastatin	54 (0.36)	53 (0.35)	52 (0.34)	43 (0.28)	47 (0.31)
Pravastatin	61 (0.40)	78 (0.51)	70 (0.46)	64 (0.42)	61 (0.4)

Compared with the non-discharge LLT group, LLT at discharge was associated with reduced risk of ischemic stroke (HR=0.65, 95% CI: 0.45-0.94, p=0.02) and stroke recurrence (HR=0.69, 95% CI: 0.48-0.99, p=0.04) at 3 months (**Table 5**).

Table 5. The association of Discharge Lipid Lowering Therapy (LLT) and outcomes

	Total	Events, (n%)	HR (95% CI) Unadjusted	P value	HR (95% CI) Adjusted	P value
3 months						
Stroke recurrence						
Discharge LLT	13248	269 (2.0%)	0.68(0.48-0.96)	0.03	0.69(0.48-0.99)	0.04
Non discharge LLT	1181	35 (3.0%)	Reference		Reference	
Ischemic stroke						
Discharge LLT	13263	245 (1.9%)	0.68(0.47-0.98)	0.04	0.65(0.45-0.94)	0.02
Non discharge LLT	1188	32 (2.7%)	Reference		Reference	
Hemorrhagic stroke						
Discharge LLT	13740	31 (0.2%)	0.71(0.25-2.01)	0.52	1.19(0.36-3.98)	0.78
Non discharge LLT	1266	4 (0.3%)	Reference		Reference	

MACE							
Discharge LLT	13248	299 (2.3%)	0.71(0.51-1.003)	0.052	0.74(0.52-1.04)	0.08	
Non discharge LLT	1181	37 (3.1%)	Reference		Reference		
12 months							
Stroke recurrence							
Discharge LLT	13248	758 (5.7%)	0.88(0.7-1.12)	0.30	0.89(0.7-1.14)	0.36	
Non discharge LLT	1181	75 (6.4%)	Reference		Reference		
Ischemic stroke							
Discharge LLT	13263	683 (5.2%)	0.87(0.68-1.11)	0.26	0.86(0.67-1.10)	0.23	
Non discharge LLT	1188	69 (5.8%)	Reference		Reference		
Hemorrhagic stroke							
Discharge LLT	13740	86 (0.6%)	0.97(0.47-2.00)	0.94	1.23(0.56-2.69)	0.60	
Non discharge LLT	1266	8 (0.6%)	Reference		Reference		
MACE							
Discharge LLT	13248	838 (6.3%)	0.94(0.75-1.19)	0.60	0.96(0.76-1.21)	0.72	
Non discharge LLT	1181	78(6.6%)	Reference		Reference		

Patients who reached the end point (stroke recurrence or MACE, death, and loss to follow-up) during hospitalization were excluded.

LDL-C goal achievement and the association of LDL-C changes (from baseline to 3 months) with outcomes at 12 months

The overall blood lipid levels at baseline and at 3-month, and 12-month follow-up were shown in **Table 6**. LDL-C goal of 1.8mmol/L was achieved by 28.3% of patients at baseline, 46.7% at 3 months, and 35.4% at 12 months; LDL-C goal of 1.4mmol/L was achieved by 13.1% of patients at baseline, 25.6% at 3 months, and 17.6% at 12 months.

Table 6. Blood Lipid Level of the included patients at baseline, 3 months and 1 year in CNSR-III

Lipids, mmol/L	Baseline N=10738	3M N=6034	12M N=4899
Median triglycerides (IQR), mmol/L	1.37(1.03-1.87)	1.32(0.98-1.81)	1.46(1.04-2.16)
Total cholesterol, mmol/L	3.97(3.31-4.72)	3.74(3.13-4.54)	3.92(3.25-4.76)
HDL-C, mmol/L	0.93(0.78-1.12)	1.02(0.86-1.21)	0.99(0.79-1.2)
LDL-C, mmol/L	2.31(1.73-2.97)	1.87(1.39-2.55)	2.14(1.57-2.87)
LDL <1.4mmol/L, n (%)	1407 (13.1)	1547 (25.6)	862 (17.6)
1.4 < LDL ≤1.8mmol/L, n (%)	1636 (15.2)	1272 (21.1)	872 (17.8)
1.8 < LDL ≤2.6mmol/L, n (%)	3655 (34.0)	1785 (29.6)	1533 (31.3)
LDL >2.6mmol/L, n (%)	4040 (37.6)	1430 (23.7)	1632 (33.3)

HDL-C: high-density lipoprotein cholesterol. LDL-C: low-density lipoprotein cholesterol.

We did not find any significant association between the LDL-C reduction rate from baseline to 3-month follow-up and the risk of stroke and MACE at 12 months (Table 7).

Table 7. Association of LDL-C changes (from baseline to 3 months) with outcomes at 12 months

Percentage of LDL level decrease (compared to baseline)	Total	Events, (n%)	HR (95% CI) unadjusted	<i>P</i> value	HR (95% CI) adjusted	<i>P</i> value
12 months						
Stroke recurrence*						
<30%, n (%)	3526	137 (3.9)	1.48 (0.92-2.39)	0.11	1.42 (0.87-2.30)	0.16
30-50%, n (%)	1146	45 (3.9)	1.50 (0.88-2.56)	0.14	1.44 (0.84-2.47)	0.19
>50%, n (%)	718	19 (2.7)	Reference		Reference	
MACE‡						
<30%, n (%)	3526	149 (4.2)	1.46 (0.92-2.20)	0.11	1.39 (0.88-2.21)	0.16
30-50%, n (%)	1146	47 (4.1)	1.41 (0.84-2.36)	0.19	1.36 (0.81-2.28)	0.24
>50%, n (%)	718	21 (2.9)	Reference		Reference	

* Patients with stroke recurrence, death, and loss to follow-up within 3 months were excluded.

‡ Patients with MACE, death, and loss to follow-up within 3 months were excluded.

Discussion

This national hospital-based study described the current LDL-C level and LLT of IS/TIA patients in the real world. We described the LLT management and LDL-C goal achievement. We also found that a lowered baseline LDL-C level was associated with a decreased risk of new ischemic stroke and MACE at both 3 months and 12 months after the initial event, without an increased risk of intracranial hemorrhage. In addition, LLT at discharge was associated with a reduced risk of CV events at 3 and 12 months. Given the large sample size of LDL-C levels of IS/TIA patients and comprehensive prognostic characteristics recorded, these findings may have important clinical implications.

1
2
3
4 Firstly, LDL-C of 1.4 mmol/l might be a reasonable target for the high-risk
5
6 population. Our study indicated that the LDL \leq 1.4 mmol/L group, with the highest
7
8 risk factors, had the lowest stroke and MACE rates at 3 and 12 months. The paradox
9
10 of high risk of stroke with low LDL-C level could be due to the previous intensive
11
12 LLT and rigid LDL-C control. It is consistent with the previous study that fixed-dose
13
14 statin regimens are less effective than targeting LDL-C levels of 1.8 or 1.4 mmol/l
15
16 when pre-treatment LDL-C levels exceed 4 mmol/L¹⁶; and the target of 1.4 mmol/l
17
18 recently advocated in particularly high-risk patients is most effective when pre-
19
20 treatment LDL-C exceeds 3 mmol/l¹⁶. In addition, 2019 ESC/EAS Guidelines for the
21
22 management of dyslipidaemias set the most aggressive target of less than 1.4 mmol/L
23
24 and a reduction of more than 50% in LDL-C¹⁷.

25
26
27 Secondly, our findings suggested that the safety of the LDL-C \leq 1.4mmol/L at least in
28
29 Chinese population, because this level was not associate with an increased risk of
30
31 hemorrhagic stroke. Studies of LDL-C and ICH have reported conflicting results. In a
32
33 twenty-year epidemiologic study, an excess risk of hemorrhagic stroke was observed
34
35 in patients with uncontrolled hypertension and LDL-C <70 mg/dL (1.8mmol/L)¹⁸.
36
37 However, in a subgroup analysis of FOURIER trial¹⁹, among patients with prior
38
39 stroke, the risk of hemorrhagic stroke did not increase, even when the median LDL-C
40
41 decreased from 2.4 mmol/L at randomization to 0.8 (0.5–1.2) mmol/L at 48 weeks in
42
43 the evolocumab group. All stroke and ischemic stroke rates were reduced, and the rate
44
45 of hemorrhagic stroke was not significantly changed. Meanwhile, in a systematic
46
47 review and meta-analysis, the higher level of LDL-C tended to be associated with a
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 lower risk of hemorrhagic stroke²⁰. Thus, our study indicated the efficacy and safety
5
6 of the baseline LDL-C of <1.4 mmol/L in IS/TIA patients, providing evidence for the
7
8 first and second prevention strategies.
9

10
11 Thirdly, we described the epidemiological characteristics of Chinese IS/TIA patients
12
13 in relation to their LDL-C levels and LLT. Compared to the study conducted in 2013
14
15
16
17²¹, our study indicated some progress in blood lipid management in mainland China.
18
19 Notably, about 97% of patients had LLT medication history prior to the entry into our
20
21 study. Also, compared to the LLT rate of 79.6% in 2013, over 90% of patients in our
22
23 cohort received LLT during hospitalization and at discharge; the LLT compliance was
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Thirdly, we described the epidemiological characteristics of Chinese IS/TIA patients in relation to their LDL-C levels and LLT. Compared to the study conducted in 2013²¹, our study indicated some progress in blood lipid management in mainland China. Notably, about 97% of patients had LLT medication history prior to the entry into our study. Also, compared to the LLT rate of 79.6% in 2013, over 90% of patients in our cohort received LLT during hospitalization and at discharge; the LLT compliance was 84.5% at 3 months, 75.6% at 6 months, and 64.8% at 12 months. In addition, LDL-C goal achievement for 1.8mmol/L had improved mildly, from 27.4% to 35.4%, and LDL-C goal achievement for 1.4mmol/L was 17.6% at 12 months. The less than perfect LLT compliance and LDL-C control rate might be due to statin intolerance in Asian people, including statin-associated myopathy and hemorrhagic stroke^{22,23}. An earlier meta-analysis indicated that statins increase the risk of hemorrhagic stroke in a medication dose-dependent and type of index brain vascular injury-dependent manner, while PCSK9 inhibitors do not increase hemorrhagic stroke risk²⁴. Thus, statins, rather than low-level of LDL-C, might closely relate to the risk of hemorrhagic stroke. Accordingly, PCSK9 inhibitors might be a more promising lipid-lowering medication class in patients with an elevated risk of hemorrhagic stroke. In addition, our analysis revealed a significant association between LLT at discharge and 3-month outcomes, indicating the importance of early LLT implementation.

1
2
3
4 Fourthly, we did not observe the correlation between the 3-month LDL-C decrease
5
6 amplitude and 12-month outcomes. To analyze the association of 3-month LDL-C
7
8 change with 12-month outcomes, we excluded subjects who reached the end point
9
10 within 3 months, which led to a reduction of our sample size and a loss of a
11
12 considerable number of target events, for most stroke recurrences occurred within 3
13
14 months²⁵. Another critical factor was that we could not adjust some risk factors in the
15
16 model, such as IL-6 level or the evidence of relevant intracranial artery stenosis
17
18 (ICAS), which were independent risk factors of the residual risk. Although
19
20 substantially reduced by secondary prevention treatment, there was still 8.3% residual
21
22 risk of 12-month recurrent stroke even in patients with persistent adherence to
23
24 guideline-based secondary stroke prevention²⁶.

25
26
27
28
29
30
31
32 Our study has several limitations. First, only LLT medication use at the follow-up
33
34 time points was recorded, whereas additional details of use during the whole study,
35
36 such as continuous use, intermittent use, and the dose changes were not subjected to
37
38 specific analysis. Thus, lipid-lowering agents use at 3 months and 12 months provided
39
40 only a partial picture of the course of medication during the study. Second, statin use
41
42 before admission was not recorded in the study which may confound the results.

43
44
45
46
47
48 Furthermore, details of medication use, such as class, dose, duration, and adherence of
49
50 lipid-lowering agents, did not enter the regression model. Third, there could be some
51
52 undetected confounding factors in addition to those regarded as the residual risk.

53
54
55
56 Forth, the use of dual antiplatelet therapy may reduce the risk of a 3-month recurrence
57
58 of stroke for more than half of the patients presented with an initial NIHSS score of
59
60

1
2
3
4 ≤3. Fifth, the study was conducted exclusively on Chinese patients. The finding in this
5
6 study needs to be further validated in studies with a larger sample size and non-Asian
7
8 populations.
9

10 11 **Conclusions**

12
13
14 The LDL-C goal achievement has increased mildly in the stroke and TIA population
15
16 in mainland China, and its further improvement is still an essential task for secondary
17
18 prevention of stroke. The lowered baseline LDL-C level was significantly associated
19
20 with a decreased short-and long-term risk of ischemic stroke among stroke and TIA
21
22 patients. LDL-C<1.4mmol/L could be a safe standard for this population.
23
24
25

26 27 **Ethics Approval Statement**

28
29
30 The study protocol of the CNSR-III was approved by the ethics committee at Beijing
31
32 Tiantan Hospital (IRB approval number: KY2015-001-01) and all participating
33
34 centers. Every participant provided written informed consent before participation.
35
36

37 38 **Acknowledgement**

39
40 We thank Dr. Feng Sheng for his important intellectual contributions to the article.
41
42 We thank all participating hospitals, their physicians, and nurses. We appreciate all
43
44 the patients who took part in the CNSR-III.
45
46
47

48 49 **Competing Interests**

50
51 The authors have no conflicts of interest to declare.
52

53 54 **Funding Sources**

55
56
57 This work was supported by the National Key R&D Program of China (No.
58
59 2018YFC1312903), National Natural Science Foundation of China (No. 81870905,
60

1
2
3
4 82071295, 81801139), and Beijing Hospitals Authority Innovation Studio of Young
5
6 Staff Funding Support (Code: 202113).
7
8

9 **Contributorship statement**

10
11 Drs. YY Xu and X Meng conceived and designed the study. Drs. X Meng and YJ
12
13 Wang served as scientific advisors. Drs. X Meng, ZX Li, Hao Li, and YJ Wang
14
15 critically reviewed the study proposal. Drs. X Meng, XQ Zhao, LP Liu, and YL Wang
16
17 collected and assembled the data. Drs. MX Wang and YS Pan did statistical analyses.
18
19 Drs. YY Xu and WQ Chen interpreted the data. Drs. YY Xu drafted the manuscript
20
21 and did the language editing. Dr. X Meng is responsible for the overall content as
22
23 guarantor. All the authors approved the final manuscript as submitted and agree to be
24
25 accountable for all aspects of the work.
26
27
28
29
30
31
32

33 **Data sharing statement**

34
35 The datasets used in this study are not publicly available, but these can be provided on
36
37 reasonable request after the approval.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference

1. Wang Y-J, Li Z-X, Gu H-Q, Zhai Y, Jiang Y, Zhao X-Q, Wang Y-L, Yang X, Wang C-J, Meng X, et al. China Stroke Statistics 2019: A Report from the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, the Chinese Stroke Association, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations. *Stroke Vasc. Neurol.* 2020;5:211–239.
2. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KMA, et al. High-dose Atorvastatin after Stroke or Transient Ischemic Attack. *N. Engl. J. Med.* 2006;355:549–559.
3. Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Béjot Y, Cabrejo L, Cha J-K, Ducrocq G, Giroud M, et al. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. *N. Engl. J. Med.* 2020;382:9.
4. Klijn CJ, Paciaroni M, Berge E, Korompoki E, Kõrv J, Lal A, Putaala J, Werring DJ. Antithrombotic Treatment for Secondary Prevention of Stroke and Other Thromboembolic Events in Patients with Stroke or Transient Ischemic Attack and Non-valvular Atrial Fibrillation: A European Stroke Organisation guideline. *Eur. stroke J.* 2019;4:198–223.

- 1
2
3
4 5. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockcroft KM, Gutierrez J,
5
6 Lombardi-Hill D, Kamel H, Kernan WN, Kittner SJ, Leira EC, et al. 2021
7
8
9 Guideline for the Prevention of Stroke in Patients with Stroke and Transient
10
11
12 Ischemic Attack: A Guideline from the American Heart Association/American
13
14 Stroke Association. *Stroke*. 2021;52:e364–e467.
15
16
- 17 6. Amarenco P, Kim JS, Labreuche J, Giroud M, Lee BC, Mahagne MH,
18
19 Nighoghossian N, Simon T, Steg PG, Touboul PJ, et al. Treat Stroke to Target
20
21
22 Trial Design: First Trial Comparing Two LDL Targets in Patients with
23
24
25 Atherothrombotic Strokes. *Eur. Stroke J*. 2019;4:271–280.
26
27
- 28 7. Qureshi AI, Caplan LR. Intracranial Atherosclerosis. *Lancet (London,*
29
30
31
32
33 *England)*. 2014;383:984–998.
34
- 35 8. Wong LKS. Global Burden of Intracranial Atherosclerosis. *Int. J. stroke Off. J.*
36
37
38
39 *Int. Stroke Soc*. 2006;1:158–159.
40
- 41 9. Mok V, Srikanth V, Xiong Y, Phan TG, Moran C, Chu S, Zhao Q, Chu WWC,
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
60 Wong A, Hong Z, et al. Race-ethnicity and Cerebral Small Vessel Disease--
Comparison between Chinese and White Populations. *Int. J. stroke Off. J. Int.*
Stroke Soc. 2014;9 Suppl A1:36–42.
10. Wolma J, Nederkoorn PJ, Goossens A, Vergouwen MDI, van Schaik IN,
Vermeulen M. Ethnicity a Risk factor? The Relation between Ethnicity and
Large- and Small-vessel Disease in White People, Black People, and Asians
within a Hospital-based Population. *Eur. J. Neurol*. 2009;16:522–527.


- 1
2
3
4 11. Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of Cholesterol-
5
6 lowering with Simvastatin on Stroke and Other Major Vascular Events in
7
8 20536 people with cerebrovascular disease or other high-risk conditions.
9
10
11
12 *Lancet (London, England)*. 2004;363:757–767.
- 13
14
15 12. Oyama K, Giugliano RP, Blazing MA, Park J-G, Tershakovec AM, Sabatine
16
17 MS, Cannon CP, Braunwald E. Baseline Low-Density Lipoprotein Cholesterol
18
19 and Clinical Outcomes of Combining Ezetimibe with Statin Therapy in
20
21 IMPROVE-IT. *J. Am. Coll. Cardiol.* 2021;78:1499–1507.
- 22
23
24
25
26 13. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy
27
28 SA, Kuder JF, Wang H, Liu T, Wasserman SM, et al. Evolocumab and Clinical
29
30 Outcomes in Patients with Cardiovascular Disease. *N. Engl. J. Med.*
31
32 2017;376:1713–1722.
- 33
34
35
36
37 14. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand A-C, Stein EA.
38
39 Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase
40
41 Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients
42
43 with Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin
44
45 Therapy. *J. Am. Coll. Cardiol.* 2012;59:2344–2353.
- 46
47
48
49
50 15. Wang Y, Jing J, Meng X, Pan Y, Wang Y, Zhao X, Lin J, Li W, Jiang Y, Li Z,
51
52 et al. The Third China National Stroke Registry (CNSR-III) for Patients with
53
54 Acute Ischaemic Stroke or Transient Ischaemic Attack: Design, Rationale and
55
56 Baseline Patient Characteristics. *Stroke Vasc. Neurol.* 2019;4:158–164.
57
58
59
60

- 1
2
3
4 16. Soran H, Adam S, Durrington PN. Optimising Treatment of Hyperlipidaemia:
5
6 Quantitative Evaluation of UK, USA and European Guidelines Taking Account
7
8 of Both LDL Cholesterol Levels and Cardiovascular Disease Risk.
9
10
11 *Atherosclerosis*. 2018;278:135–142.
12
13
14
15 17. (EAS) TTF for the management of dyslipidaemias of the ESC of C (ESC) and
16
17 EAS. 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid
18
19 Modification to Reduce Cardiovascular Risk. *Atherosclerosis*. 2019;290:140–
20
21 205.
22
23
24
25
26 18. Zhang X, Liu J, Wang M, Qi Y, Sun J, Liu J, Wang Y, Hao Y, Li Y, Zhou M,
27
28 et al. Twenty-year Epidemiologic Study on LDL-C Levels in Relation to the
29
30 Risks of Atherosclerotic Event, Hemorrhagic Stroke, and Cancer Death among
31
32 Young and Middle-aged Population in China. *J. Clin. Lipidol*. 2018;12:1179-
33
34 1189.e4.
35
36
37
38
39 19. Giugliano RP, Pedersen TR, Saver JL, Sever PS, Keech AC, Bohula EA,
40
41 Murphy SA, Wasserman SM, Honarpour N, Wang H, et al. Stroke Prevention
42
43 with the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor
44
45 Evolocumab Added to Statin in High-Risk Patients With Stable
46
47 Atherosclerosis. *Stroke*. 2020;51:1546–1554.
48
49
50
51
52
53 20. Wang X, Dong Y, Qi X, Huang C, Hou L. Cholesterol Levels and Risk of
54
55 Hemorrhagic Stroke: a Systematic Review and Meta-analysis. *Stroke*.
56
57 2013;44:1833–1839.
58
59
60

- 1
2
3
4 21. Wang C-J, Wang Y-L, Li Z-X, Wang Y-J. The Management of LDL
5
6 Cholesterol and Predictors of Goal Achievement in Stroke Patients in China: A
7
8 Cross-Sectional Study. *CNS Neurosci. Ther.* 2016;22:577–583.
9
10
11
12 22. Tomlinson B, Chan P, Liu Z-M. Statin Responses in Chinese Patients. *J.*
13
14 *Atheroscler. Thromb.* 2018;25:199–202.
15
16
17 23. Tomlinson B, Chan P, Liu Z-M. Statin Intolerance-An Asian Perspective. *J.*
18
19 *Atheroscler. Thromb.* 2020;27:485–488.
20
21
22
23 24. Sanz-Cuesta BE, Saver JL. Lipid-Lowering Therapy and Hemorrhagic Stroke
24
25 Risk: Comparative Meta-Analysis of Statins and PCSK9 Inhibitors. *Stroke.*
26
27 2021;52:3142–3150.
28
29
30
31 25. Coull AJ, Lovett JK, Rothwell PM. Population Based Study of Early Risk of
32
33 Stroke after Transient Ischaemic Attack or Minor Stroke: Implications for
34
35 Public Education and Organisation of Services. *BMJ.* 2004;328:326.
36
37
38
39 26. Pan Y, Li Z, Li J, Jin A, Lin J, Jing J, Li H, Meng X, Wang Y, Wang Y.
40
41 Residual Risk and Its Risk Factors for Ischemic Stroke with Adherence to
42
43 Guideline-Based Secondary Stroke Prevention. *J. stroke.* 2021;23:51–60.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Dose-response-relationship curves

Adjusted odds ratio of events and MACE at 3 months and 12 months according to LDL-C at baseline in patients. (a) stroke at 3 months; (b) ischemic stroke at 3 months; (c) hemorrhagic stroke at 3 months; (d) MACE at 3 months; (e) stroke at 12 months; (f) ischemic stroke at 12 months; (g) hemorrhagic stroke at 12 months; (h) MACE at 12 months. The full line indicates the adjusted hazard ratio and the dashed lines the 95% confidence interval bands. Reference is LDL-C >2.6mmol/L. Data were fitted using a logistic regression model of restricted cubic spline with three knots (the 5th, 50th, 90th percentiles) for LDL-C level, adjusting for potential covariates.



Dose-response-relationship curves

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	1 3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	7 N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8
Bias	9	Describe any efforts to address potential sources of bias	9
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	10 10 10 11 N/A
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	11 N/A N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	11 N/A 12
Outcome data	15*	Report numbers of outcome events or summary measures over time	13

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	13
2			(b) Report category boundaries when continuous variables were categorized	13
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	14
4				
5	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	14
6				
7				
8				
9				
10				
11	Discussion			
12	Key results	18	Summarise key results with reference to study objectives	17
13	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	20
14				
15	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	18
16				
17	Generalisability	21	Discuss the generalisability (external validity) of the study results	18
18				
19				
20				
21	Other information			
22	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	21
23				
24				

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.